Pesquisar este blog


sexta-feira, 31 de outubro de 2014

Targeted Grand Challenges: A Turning Point for the National Nanotechnology Initiative

Written by Jeff Morse, Ph.D.
October 30, 2014
ImageThe conclusions and recommendations by the Presidential Council of Advisors on Science & Technology (PCAST) in the fifth assessment of the National Nanotechnology Initiative (NNI) has determined that a turning point has been reached. In a future vision wherein the ability to understand and control matter at the nanoscale enables a revolution in technology providing significant societal and economic benefit, the Federal Government must transition its activities toward facilitating commercialization. As such, PCAST recommends a strategy of targeting specific nanotechnology Grand Challenges though a framework partnership between the public and private sector that would effectively drive scientific advances to revolutionary commercialized products.
Capturing excerpts of the strongly focused language in the report;
…the primary conclusion of the 2014 PCAST review is that the U.S. will only be able to claim the rewards that come from investing in nanotechnology research and sustaining an overarching Federal initiative if the Federal interagency process, the Office of Science and Technology Policy (OSTP), and the agencies themselves transition their nanotechnology programmatic efforts beyond supporting and reporting on basic and applied research and toward building program, coordination, and leadership frameworks for translating the technologies into commercial products.
These observations and recommendations are highly welcomed throughout the nanomanufacturing community as stakeholders seek to develop new approaches and models to transition the gap for translating the discoveries of S&T investments to commercially viable nano-enabled products to realize the NNI’s vision. Grand Challenges target specific technical goals while incorporating the active management needed to accomplish them, such an approach can provide the necessary framework for commercialization opportunities to mature. The report cited example Grand Challenges for nanotechnology including nano-enabled desalination of seawater to solve the emerging water crisis, reducing global greenhouse emissions with nano-enabled solid-state refrigeration, creating a forefront of manufacturing through nano-3D printing, and developing a nanoscale therapeutic for at least one major cancer.
The PCAST emphasized their belief that the recommendation contained in the 2014 review, in particular the enhanced focus on the transition to commercialization, the implementation of the Grand Challenges framework, and more aggressive leadership, were essential for a successful NNI 2.0 for the coming decade.
In further support of the nanomanufacturing community, the PCAST report recommended at least one Grand Challenge should contain program elements aimed at manufacturing challenges specific to that focus area. In particular, the Nanoscale Science, Engineering, and Technology (NSET) Subcommittee should work with the Federal agencies to define potential Manufacturing Innovation Institutes dedicated to nanoscience and nanotechnology as part of the National Network for Manufacturing Innovation (NNMI) program. As the challenges in manufacturing are likely to impede commercializing advanced nanomaterials, nanomedicine, and other nanotechnologies unless the Federal Government addresses the valley of death, which involves the need for nanofabrication facilities to create high volumes of nanotechnology product.
Citing the lack of progress against the recommendations from the 2012 assessment , the 2014 provides directed recommendations towards achieving the NNI’s vision, including creating and executing a process to engage research, development, and industrial stakeholders in the identification and selection of Grand Challenges on an ongoing basis.
Additional recommendations in the report targeted alleviating key constraints on nanotechnology commercialization with particular on enhancement of the nanotechnology ecosystem. One primary constraint, which the NNN has supported for some time, is Investment in nanofabrication facilities. As the commercialization of nanotechnology innovations depends heavily on the successful development of nanofabrication and nanomanufacturing procedures, few nanomanufacturing user facilities are accessible for developing production procedures, scaling up volumes of nanomaterial for research, or generating commercial supply. The lack of such an ecosystem in the absence of these facilities requires start‐ups to assume significant up‐front financial risk in developing in‐house facilities to support company operations. A versatile network of facilities employing both established and emerging nanomanufacturing tools and expertise would accelerate the innovation pipeline for translational nanotechnology R&D. The second key constraint cited was the need for Comprehensive nanotechnology EHS standards, which additionally would provide clear protocols with respect to risk assessment and regulatory landscape for nano-enabled product development.
Along with the key constraints cited above, the report discussed several general constraints to nanotechnology commercialization including:
  • The need to train first-time academic entrepreneurs in moving a technical innovation out of the research laboratory into a small company;
  • Communication among stakeholders-Successful academic investigators understand the technical landscape and the potential value of their work, but they may not know how their innovations might address strategic gaps at a large technology company or could be translated into a commercial success. A company R&D director, conversely, might know little about a high-value technology being developed in an academic laboratory. Additional venues are needed to bring together academic entrepreneurs, VCs, industry, relevant Government agencies, and other stakeholders;
  • Venture capital for new entrepreneurs
  • Peer review of high-risk, high-return ideas
In support of NNI activities addressing these constraints, the PCAST report cited the efforts of the National Nanomanufacturing Network, emphasizing the NSF funding of the four Nano Science and Engineering Research Centers (NSECs) that focus on nanomanufacturing (two centers will retire in 2014 and the other two will retire in 2015 and 2016), which with our National Lab partners at NIST and DOE, along with other affiliates and stakeholders, share information, organize annual nanomanufacturing conferences and workshops, and establish a cross cutting community of practice.
Last updated: October 30, 2014

Fonte: InterNano

First human clinical trial of nanoparticles highlights their safety

Science cover
V. Altounian, C. Bickel/Science Translational Medicine
A report on the first human clinical trial of C Dots is featured on the Oct. 29 cover of the journal Science Translational Medicine.
Nanoparticles designed to adhere to and light up cancer cells have reached a major milestone in their bench-to-bedside journey. A first clinical trial of these ultrasmall, multifunctional particles has deemed them safe for humans and cleared easily by the body.
The particles, called “C dots” (Cornell dots), were invented more than a decade ago by Uli Wiesner, the Spencer T. Olin Professor of Materials Science and Engineering. They have been undergoing a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) human clinical trial since 2010. The results of that study, which involved five patients with melanoma, were published Oct. 29 in Science Translational Medicine and featured on the journal’s cover.
For the trial, which has been conducted at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, the 7-nanometer particles were labeled with radioactive iodine and injected into patients with metastatic melanoma. The iodine allowed the particles to be tracked with positron emission tomography (PET). Administered under the FDA’s IND guidelines, the study showed that the particles are safe for human use and leave no trace after renal excretion – an important benchmark for any substance undergoing IND approval. The trial has been amended to include patients with brain tumors, and those patients are being recruited now.
“This has been very encouraging,” Wiesner said. “It’s the first case we’re aware of in which the FDA has approved an inorganic optical nanoparticle as an IND for a clinical trial. While this was just a safety and pharmacokinetics study, this opens the door to using these particles in real applications.
Their intended use, as a cancer diagnostic tool, is now undergoing a separate human clinical trial at MSKCC that involves metastatic melanoma patients with head and neck lesions. That trial employs a handheld camera for surgeons in conjunction with the glowing C dots as the fluorescent probes to enable the surgeons to make better decisions about which lymph nodes to remove and which to leave in. “We are very excited about these new optical tools in the surgery room,” said MSKCC’s Dr. Michelle Bradbury, who is overseeing the trial.
C dots are silica-organic hybrid particles that consist of fluorescent molecules encapsulated in a silica core and surrounded by a silica shell, which in turn is coated with polyethylene glycol (PEG). To turn these core-shell particles into cancer probes, some of the PEG chains carry peptides that bind to overexpressed receptors on tumor surfaces. When exposed to near-infrared light, the bound particles fluoresce and serve as an optical beacon for surgeons.
Beyond their diagnostic and surgical potential, C dots also could be used as highly specific drug deliverers. By binding only to tumor cells, they would release drugs only where they are needed, rather than systemically, as with most cancer treatments today.
Though this first trial’s results were positive, Wiesner stressed that C dots are still years away from final FDA approval, as many follow-up studies are required that involve many more patients.
The study, “Clinical Translation of an Ultrasmall Inorganic Optical-PET Imaging Nanoparticle Probe,” was done in collaboration with Bradbury at MSKCC, with whom Wiesner has worked for eight years on the C dots’ surgical applications. The work was funded by the Laurent and Alberta Gershel PET Imaging Center of MSKCC.

De Nano para Micro?

Por: André Luiz Aguiar*

Progredimos da Nanotecnologia
para a Microtecnologia!

A pergunta que faço é a seguinte: MICRO ficou mais "potente" e melhor que NANO?

O desenvolvimento de produtos está tão avançado que já estão trabalhando na escala NANO. E nos afirmaram, categoricamente, que quanto mais diminuta uma partícula mais eficiente ela será.

Mas desde quando as empresas "acharam" melhor trabalhar com MICRO e abandonar NANO?

Vejam na escala de grandeza ao lado que micro está acima do nano e o yocto seria o limite. E, portanto, mais potente seria um produto que chegasse na fronteira desta eficiência.    

Quando veio o desenvolvimento em Nanotecnologia, diversas marcas quiseram associar sua indústria ao termo "Nano". 

-- Imagina!!! Minha empresa ficar de fora dessa bocada! Era o que deduziam as grandes marcas.

Passado algum tempo, ao invés disso, algumas marcas começaram a "fugir" do Nano e agora anunciam apenas Micro.

Já escrevi aqui no blog que estavam indo até a Picotecnologia e eu propunha, então, para apelar de vez, que fôssemos para a Plancktecnologia (veja aqui: Picotecnologia ou Nanotecnologia?).

Estou falando especificadamente de anúncios a respeito de xampus.

Para que vocês confiram, assistam aos anúncios abaixo:

Propaganda 1) Xampu com Picotecnologia
Veja aqui

Propaganda 2) Xampu com Nanotecnologia
Veja aqui

Propaganda 3) Xampu com Microtecnologia
Veja aqui

O que será que aconteceu? A nanotecnologia acabou se tornando pior?
Será que eles descobriram que Micro é melhor?

Ou apenas perceberam que, comercialmente, veicular Micro para sua marca é mais "forte" e vendável?

Os consumidores conhecem mais algo que é micro do que aquilo que é nano. Isso é notório.

Era comum ouvir antigamente, quando a criança brincava na terra, a mãe dizer: 
--- Vai lavar essa mão antes de comer muleque. Tua mão tá cheia de germes! Deve tá cheio de micróbio!

Estes germes/micróbrios eram sempre associados a coisas pequenas e que faziam mal. E a palavra "científica" que mais se aproximava de germes e de algo que era pequeno, seria dizer que aquilo era micro. Notem a palavra usada pela hipotética mãemicróbio

Ou seja, os consumidores começaram a associar que os cientistas eram tão bons que eles conseguiram fazer esse micróbio (que na cabeça da geral era ruim) se tornar um MicroBOM.

Portanto, o consumidor vai associar muito melhor um xampu que seja micro do que aquele que seja nano. Pois os cientistas foram tão craques que fizeram aquele micróbio se tornar ótimo para eu poder usar na minha cabeleira!

Assim, em "marketing familiar", você nunca ouviria um pai dizer: tua mão tá cheio de nano piá! e causar o mesmo impacto ao dizer: tua mão tá cheio de micróbio!

O Micro soa melhor! MicroOndas, MicroCelular, MicroSsaia, MicroComputador, MicroCirurgia, MicroÔnibus, MicroProcessador, MicroRregião, MicroScópio, MicroOrganismo,...  

Brincadeiras à parte, basicamente é o seguinte: as empresas estão assustadas com o movimento de controle e anúncios de precaução, bem como aos possíveis riscos que a Nanotecnologia pode ocasionar. Aí, eles decidiram "voltar" ao Micro. Pois, além de mais comercial e fisgador aos consumidores, não vai gerar tanto alarde se eles estão ou não lidando com Nanotecnologia ou algo menor.

Afinal, você como consumidor tem como verificar se o teu xampu tem nano ou micropartículas?

Se eles estiverem usando Femto, Atto, Zepto, Yocto, Pico, Nano e disserem/anunciarem ser algo "maravilhosamente" MICRO para vender mais, você terá como verificar a autenticidade?

Vamos relembrar o nosso Código de Defesa do Consumidor (Lei 8.078 de 1990)?

Art. 6º São direitos básicos do consumidor:
        I - a proteção da vida, saúde e segurança contra os riscos provocados por práticas no fornecimento de produtos e serviços considerados perigosos ou nocivos;
        II - a educação e divulgação sobre o consumo adequado dos produtos e serviços, asseguradas a liberdade de escolha e a igualdade nas contratações;
       III - a informação adequada e clara sobre os diferentes produtos e serviços, com especificação correta de quantidade, características, composição, qualidade, tributos incidentes e preço,bem como sobre os riscos que apresentem
        IV - a proteção contra a publicidade enganosa e abusiva, métodos comerciais coercitivos ou desleais, bem como contra práticas e cláusulas abusivas ou impostas no fornecimento de produtos e serviços; [grifei].

 Cuidado com este Micróbio pessoal!

*André Luiz Aguiar: advogado formado pela 
Pontifícia Universidade Católica do 
Paraná (PUC-PR), OAB-PR 60.581,
pesquisador e consultor 
Nanotecnologias e regulamentação 

a) O que é nanotecnologia para os cabelos

b) Nanotecnologia aplicada aos cosméticos-UFPR
c) Variety and diversity of nanotechnologies
d) Nano & the top 10 big cosmetics companies : L’Oréal, Procter & Gamble and Henkel on the podium for patents
e) FOEA takes nano-cosmetics safety concerns to the L’Oreal-sponsored catwalk

quarta-feira, 29 de outubro de 2014

Nanosafety research – there’s room for improvement

The quest for the gold standard

Iron oxide nanoparticles on the surface of a cell (source: Empa).

Empa toxicologist Harald Krug has lambasted his colleagues in the journal Angewandte Chemie. He evaluated several thousand studies on the risks associated with nanoparticles and discovered no end of shortcomings: poorly prepared experiments and results that don’t carry any clout. Instead of merely leveling criticism, however, Empa is also developing new standards for such experiments within an international network.

Researching the safety of nanoparticles is all the rage. Thousands of scientists worldwide are conducting research on the topic, examining the question of whether titanium dioxide nanoparticles from sun creams can get through the skin and into the body, whether carbon nanotubes from electronic products are as hazardous for the lungs as asbestos used to be or whether nanoparticles in food can get into the blood via the intestinal flora, for instance. Public interest is great, research funds are flowing – and the number of scientific projects is skyrocketing: between 1980 and 2010, a total of 5,000 projects were published, followed by another 5,000 in just the last three years. However, the amount of new knowledge has only increased marginally. After all, according to Krug the majority of the projects are poorly executed and all but useless for risk assessments.

How do nanoparticles get into the body?
Artificial nanoparticles measuring between one and 100 nanometers in size can theoretically enter the body in three ways: through the skin, via the lungs and via the digestive tract. Almost every study concludes that healthy, undamaged skin is an effective protective barrier against nanoparticles. When it comes to the route through the stomach and gut, however, the research community is at odds. But upon closer inspection the value of many alarmist reports is dubious – such as when nanoparticles made of soluble substances like zinc oxide or silver are being studied. Although the particles disintegrate and the ions drifting into the body are cytotoxic, this effect has nothing to do with the topic of nanoparticles but is merely linked to the toxicity of the (dissolved) substance and the ingested dose.

Laboratory animals die in vain – drastic overdoses and other errorsKrug also discovered that some researchers maltreat their laboratory animals with absurdly high amounts of nanoparticles. Chinese scientists, for instance, fed mice five grams of titanium oxide per kilogram of body weight, without detecting any effects. By way of comparison: half the amount of kitchen salt would already have killed the animals. A sloppy job is also being made of things in the study of lung exposure to nanoparticles: inhalation experiments are expensive and complex because a defined number of particles has to be swirled around in the air. Although it is easier to place the particles directly in the animal’s windpipe (“instillation”), some researchers overdo it to such an extent that the animals suffocate on the sheer mass of nanoparticles.
While others might well make do without animal testing and conduct in vitro experiments on cells, here, too, cell cultures are covered by layers of nanoparticles that are 500 nanometers thick, causing them to die from a lack of nutrients and oxygen alone – not from a real nano-effect. And even the most meticulous experiment is worthless if the particles used have not been characterized rigorously beforehand. Some researchers simply skip this preparatory work and use the particles “straight out of the box”. Such experiments are irreproducible, warns Krug.

The solution: inter-laboratory tests with standard materialsEmpa is thus collaborating with research groups like EPFL’s Powder Technology Laboratory, with industrial partners and with Switzerland’s Federal Office of Public Health (FOPH) to find a solution to the problem: on 9 October the “NanoScreen” programme, one of the “CCMX Materials Challenges”, got underway, which is expected to yield a set of pre-validated methods for lab experiments over the next few years. It involves using test materials that have a closely defined particle size distribution, possess well-documented biological and chemical properties and can be altered in certain parameters – such as surface charge. “Thanks to these methods and test substances, international labs will be able to compare, verify and, if need be, improve their experiments,” explains Peter Wick, Head of Empa’s laboratory for Materials-Biology Interactions.
Instead of the all-too-familiar “fumbling around in the dark”, this would provide an opportunity for internationally coordinated research strategies to not only clarify the potential risks of new nanoparticles in retrospect but even be able to predict them. The Swiss scientists therefore coordinate their research activities with the National Institute of Standards and Technology (NIST) in the US, the European Commission’s Joint Research Center (JRC) and the Korean Institute of Standards and Science (KRISS).

Fonte: EMPA

Nano Google: inside the Human Body

by Jamie Hartford

The leader of the life sciences team at the Google[x] research lab unveiled the company’s Nanoparticle Platform, an ambitious plan to revolutionize the way diseases are diagnosed.

Google[x]'s Andrew Conrad speaks about the Nanoparticle
Platform at the WSJD Live Conference in Laguna Beach, CA.
If you already thought Google was everywhere, just wait until you see where the Web search giant is planning to go next: inside the human body.
Speaking today at the WSJD Live Conference in Laguna Beach, CA, Andrew Conrad, who leads the life sciences team at the secretive Google[x] research lab, revealed an ambitious project called the Nanoparticle Platform, which aims to create controllable nanoparticles that can be deployed inside the body to diagnose diseases.
“It’s a little more complicated than the contact lens,” Conrad said, referring to the smart contact lenses the company designed to monitor glucose levels, which it recently licensed to Novartis.
He explained that nanoparticles, which are so small that thousands of them can fit within a red blood cell, are “the nexus between biology and engineering, so we can make these nanoparticles behave in ways we want them to do.”
The idea is to load magnetic nanoparticles with antibodies and place them in a pill. Once the pill is swallowed, the nanoparticles would course through the body before being “recalled “ by placing a magnet to the person’s wrist.
“We call them back to one place, and we ask them, ‘Hey, what did you see? Did you find cancer? Did you see something that looks like a fragile plaque for a heart attack? Did you see too much sodium?’” Conrad said in video from the event.
The Nanoparticle Platform has the potential to disrupt the way medicine is practiced. Conrad compared the current healthcare model to trying to learn about Parisian culture by flying a helicopter over Paris once a year. “That’s what doctors do now,” he said. “What we’re hoping to do is these little particles go out and mingle with the people.”
Vídeo HERE

Jamie Hartford, managing editor, MD+DI
Fonte: MD+DI

segunda-feira, 27 de outubro de 2014

Belgium Publishes Decree on the Nanomaterial Register

The Belgian Royal Decree Regarding the Placement on the Market of Substances Manufactured at the Nanoscale, a Report to the King, and the Opinion of the Council of State were published in the September 24, 2014, issue of the Official Gazette. 

Substances defined as nanomaterials, and mixtures containing them, must be registered by the Belgian Federal Public Service for Health, Food Chain Safety and the Environment if at least 100 grams of the substance or mixture is placed on the market during the year covered by the registration, and if the entity putting the substance on the market produced this substance or mixture, or puts it on the market for professional users only. 

Biocidal products, medicines, food and feed, food contact materials, and pigments are excluded from the scope of the Royal Decree. 

Nanomaterials subject to declaration requirements must be registered by January 1, 2016, if they are already on the market by this date. After January 1, 2016, all nanomaterials concerned must be registered before being placed on the market. Mixtures subject to declaration requirements must be registered by January 1, 2017, if they are already on the market by this date. After January 1, 2017, all mixtures concerned must be registered before being placed on the market.


sexta-feira, 24 de outubro de 2014

Physicochemical characteristics of nanomaterials that affect pulmonary inflammation

Physicochemical characteristics of nanomaterials that affect pulmonary inflammation

Hedwig M Braakhuis12*Margriet VDZ Park1Ilse Gosens1Wim H De Jong1 andFlemming R Cassee13

1National Institute for Public Health and the Environment (RIVM), PO Box 1, Bilthoven 3720BA, The Netherlands
2Department of Toxicogenomics, Maastricht University, PO Box 616, Maastricht 6200MD, The Netherlands
3Institute of Risk Assessment Sciences, Utrecht University, PO Box 80.163, Utrecht 3508TD, The Netherlands
For all author emails, please log on.

Particle and Fibre Toxicology 2014, 11:18  doi:10.1186/1743-8977-11-18

The electronic version of this article is the complete one and can be found online at:

Received:7 October 2013
Accepted:4 April 2014
Published:11 April 2014
© 2014 Braakhuis et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.


The increasing manufacture and use of products based on nanotechnology raises concerns for both workers and consumers. Various studies report induction of pulmonary inflammation after inhalation exposure to nanoparticles, which can vary in aspects such as size, shape, charge, crystallinity, chemical composition, and dissolution rate. Each of these aspects can affect their toxicity, although it is largely unknown to what extent. The aim of the current review is to analyse published data on inhalation of nanoparticles to identify and evaluate the contribution of their physicochemical characteristics to the onset and development of pulmonary inflammation. Many physicochemical characteristics of nanoparticles affect their lung deposition, clearance, and pulmonary response that, in combination, ultimately determine whether pulmonary inflammation will occur and to what extent. Lung deposition is mainly determined by the physical properties of the aerosol (size, density, shape, hygroscopicity) in relation to airflow and the anatomy of the respiratory system, whereas clearance and translocation of nanoparticles are mainly determined by their geometry and surface characteristics. Besides size and chemical composition, other physicochemical characteristics influence the induction of pulmonary inflammation after inhalation. As some nanoparticles dissolve, they can release toxic ions that can damage the lung tissue, making dissolution rate an important characteristic that affects lung inflammation. Fibre-shaped materials are more toxic to the lungs compared to spherical shaped nanoparticles of the same chemical composition. In general, cationic nanoparticles are more cytotoxic than neutral or anionic nanoparticles. Finally, surface reactivity correlates well with observed pulmonary inflammation. With all these characteristics affecting different stages of the events leading to pulmonary inflammation, no unifying dose metric could be identified to describe pulmonary inflammation for all nanomaterials, although surface reactivity might be a useful measure. To determine the extent to which the various characteristics influence the induction of pulmonary inflammation, the effect of these characteristics on lung deposition, clearance, and pulmonary response should be systematically evaluated. The results can then be used to facilitate risk assessment by categorizing nanoparticles according to their characteristics.
Nanoparticles; Inhalation exposure; Pulmonary toxicity; Particle characteristics; Surface reactivity; Risk assessment


In recent years, a large number of nanotechnology-enabled products have entered the global marketplace. In March 2011, the Nanotechnology Consumer Products Inventory contained 1317 products or product lines from over 30 countries, a growth of nearly 521% (from 212 to 1317 products) since the Inventory was first released in March 2006 [1]. Exposure to nanomaterials is on the rise, and because of uncertainty regarding their toxic characteristics, concerns have arisen that such materials pose new health risks for consumers, workers, and the environment.
An adequate risk assessment of nanomaterials requires information on both the exposure and hazard of their component particles. Inhalation is considered to be an important route of exposure to nanoparticles [2,3], especially in occupational settings. Many products, such as sprays, may likewise lead to inhalation by consumers [4,5]. With regard to hazard, numerous in vitro and in vivo studies have been conducted to determine whether inhalation of nanoparticles causes adverse effects. The most reported effect is pulmonary inflammation, largely indicated by an influx of neutrophils that can be observed in the bronchoalveolar lavage fluid in vivo and the induction of inflammatory cytokines in in vitro lung models eg. [6-13].
Nanomaterials are composed of primary and agglomerated particles that can vary in size, shape, charge, crystallinity, chemical composition and other characteristics, and this variety will increase even further in the future [14]. All these characteristics have been suggested to affect the toxicity of nanomaterials, but not all existing and emerging types of nanomaterials can be tested separately in studies to evaluate their safety. The current review therefore seeks to identify trends regarding their characteristics and pulmonary inflammation, as a key hazard indicator, by analysing published data on inhalation of nanoparticles. Ideally, this includes in depth analysis of characteristics that influence the mechanism underlying pulmonary inflammation e.g. that affect chemotactic signalling. Unfortunately, little information exists to elucidate the role of specific particle properties on details of the mechanism such as chemotactic signals. For this reason, we have limited our analysis to more generally reported effects of pulmonary inflammation and phagocytosis at a larger scale. The exposure assessment of nanomaterials, which is of major importance for the risk assessment of nanomaterials, is out of the scope of this review. As the induction of pulmonary inflammation results from a combination of their deposition, clearance, and interactions in the lungs, the characteristics influencing one or more of these processes will be discussed using data of peer reviewed papers. Ultimately, these results can be used to design safer nanomaterials and to identify those that need to be investigated further in terms of their health risks. For the risk assessment of nanomaterials, knowledge on toxicity-determining characteristics will help to categorise nanomaterials into hazard groups according to these characteristics.
Comparison across studies is often difficult due to the use of different experimental protocols and choice of endpoints, which largely influences the results. Therefore, our approach was to focus on investigations of multiple nanoparticles differing in one physicochemical characteristic within the same in vivo study. These studies are summarised in Table 1. We are aware of the fact that some studies use rather high exposures. Since there is no scientific consensus on when exposures are no longer realistic, and for the sake of including as much information as possible, we did include these studies in our review. In addition, we included both inhalation and intratracheal instillation studies. Since the dose rate together with the clearance rate will be the main driver for the retained dose, intratracheal instillation may lead to different effects than when using inhalation of aerosols; when available, the retained doses in the lungs are included.
Table 1. Inhalation studies investigating the effect of nanomaterial characteristics on lung deposition, clearance, and/or pulmonary inflammation

Deposition of nanoparticles in the lungs

A primary or individual nanoparticle (also called “ultrafine particle”) has a mean primary diameter of <;100 nm, compared to ;>1 μm for a microparticle (also called “fine particle”). Primary particles tend to agglomerate, or aggregate, into larger particles. As they travel through the air from the point of generation to the point of exposure, the size of the primary and agglomerated particles determines their lung deposition pattern. (Figure 1[45-47]. When nanoparticles are agglomerated in air, measurements of nanoparticle size will give the size of the agglomerates and not the primary particles [48]. The size of the agglomerates can be measured with different techniques, depending on the size of the agglomerates. Optical particle sizers (OPS) and aerodynamic particle sizers (APS) can measure the aerodynamic particle size ranging from 300 nm to 10 μm or 500 nm to 10 μm, respectively [49,50]. The aerodynamic particle size is mostly given as a mass median aerodynamic diameter (MMAD). Differential mobility analysers (DMA) and scanning mobility particle sizers (SMPS) can measure the electrical mobility diameter of particles ranging from 2.5 nm to 1 μm, depending on the type of SMPS used. The electrical mobility diameter is mostly given as a count median diameter (CMD). The aerodynamic size depends not only on the physical size of the particles but also on the density of the particles, while the electrical mobility size depends on the physical size alone [50].
thumbnailFigure 1. Deposition of particles in different regions of the lung depends on particle size and density. Particle size ranges from 1 nm to 100 μm, particle density tested: 0.1 g/cm3 (left panel), 1.0 g/cm3(centre panel) and 10.0 g/cm3 (right panel) (Simulation made in Multiple Pathway Particle Dosimetry Model V2.1 Copyright ARA 2009, based on human oronasal-normal augmenter breathing). The figure shows the deposition of inhaled particles in the extra-thoracic region (black line), the tracheobronchial region (grey line), and the alveolar region (red line). In the alveolar region, the deposition is the highest for nanoparticles with a primary or agglomerate particle size between 10 nm and 100 nm, regardless of the density. For particles with a primary or agglomerate size between 100 nm and 1 μm, the (agglomerate) density influences the deposition in the lungs: in this size range particles/agglomerates with a higher density will deposit more efficiently in the alveolar region compared to particles/agglomerates with a lower density.
Nanoparticles with a primary or agglomerate particle size between 10 and 100 nm will deposit more efficiently in the alveolar region compared to particles with an agglomerate particle size between 0.1 and 1 μm [45-47,51]. In the alveoli the airflow is minimal, therefore, for nanoparticles between 10 and 100 nm, the mechanism of deposition in the lungs is diffusion [52]. Several in vivoinhalation studies [10,16,17,21] show that particles of smaller agglomerate size deposit more efficiently in the alveolar region than those of larger agglomerate size. Particles that differ in primary particle size but have the same agglomerate diameter show similar deposition fractions[18,22,27,32]. As stated above, for agglomerated nanoparticles with an aerodynamic size above 300 nm, the density affects deposition. For these large agglomerates, increasing the density increases their deposition in the lungs, including in the alveolar region (Figure 1). It should be noted that the density of agglomerated particles is lower than the material density of the particles itself. Shape is also a factor. Primary and agglomerated nanoparticles occur in forms such as spheres, rods, fibres, wires, belts, triangles, and platelets. Shapes with a high aspect ratio, like fibres, have an aerodynamic size that is about three times their actual diameter; long fibres can deposit in the upper airways due to interception by touching the surface of the airways [53,54].
For particles to induce pulmonary inflammation, they must deposit in the alveolar region. When the agglomerate size of nanoparticles is <;100 nm but above 10 nm, a considerable part of them will deposit in the alveolar region (about 30% of the particles) [45,46,55]. Although below 30 nm, the deposition shifts from the alveoli more towards the tracheobronchial region.
Using the above information, one can predict the dose of nanomaterials in the lung by using the Multiple Pathway Particle Dosimetry model (MPPD model). The model uses the morphology of the lung, respiratory conditions, and particle size (either CMD or MMAD), particle density, and exposure concentration to predict deposition in the various regions of the lung [51]. The exposure concentration determines the total amount of the nanoparticles that will deposit in the different regions of the lungs; it does not directly influence the deposition fraction in different regions of the lungs. It is important to note that the MPPD model gives an approximation of the deposition of particles in the lungs and results should be viewed with caution. For example, Figure 1 shows extra-thoracic deposition of 1 nm particles and no tracheobronchial or alveolar deposition in humans during oronasal breathing, while there is substantial deposition of 1 nm particles in the tracheobronchial region in humans during oral breathing (about 24%) [46]. In addition, nanoparticles can be polydispersed in the air, resulting in a range of agglomerate sizes within a cloud of nanoparticles. When selecting CMD in the MPPD model, the polydispersity of the particles is not taken into account and the resulting lung deposition pattern should be interpreted as an estimation with uncertainties.
Another complicating factor is that nanoparticle agglomerate size changes over time by coagulation in air. The process is predominantly determined by Brownian motion and depends on the concentration of particles as they travel from site of generation to site of exposure; it also depends on the time required to reach the exposure site [56]. Nanomaterials are generated with a certain primary particle size but then tend to agglomerate, resulting in a lower number of particles with an increasing agglomerate size. The higher the particle number at generation, the faster these agglomerates are formed: nanoparticles of 30 nm primary size at a number concentration of 107particles/cm3 are stable for a maximum of 10 seconds, while the same nanoparticles at a number concentration of 106 particles/cm3 are stable for a maximum of 100 seconds [57]. With longer travel times, the agglomerates increase in size. The speed and extent of agglomeration also depend on nanoparticle characteristics like surface charge, type of coating, and hygroscopicity. Particles with the same surface charge repel each other, whereas neutral particles more easily agglomerate. Similar, coatings can cause nanoparticles to repel or attract. Hygroscopicity describes particle response to water molecules in the environment, depending on the relative humidity. For example, they may attract molecules and grow many times their original size at increasing relative humidity [58], or they may lose their own water content to evaporation, shrinking in size, at decreasing relative humidity.
When the influence of particle size is investigated, it should be measured as closely as possible to the site of exposure and not at the site of generation as a primary nanoparticle may constantly change its agglomerate size. After deposition of inhaled nanoparticles, agglomeration usually plays a minor role since the peripheral lung surface area is so large that the probability of two nanoparticles landing on each other is rather low for a diffusion-driven deposition. This is in contrast to deposition patterns of larger particles, which often congregate in ‘hot-spots’. The binding kinetics of proteins as influenced by nanoparticle charge and other physicochemical properties of the surface is the more important mechanism after deposition. In animal studies the lung deposition can be measured, while in humans the deposition of particles in the different regions of the lungs can be modelled by the MPPD model. The results of the MPPD model should be interpreted with caution, as they are an estimation of what happens in reality.

Clearance of nanomaterials from the lungs

When nanoparticles are not exhaled, but deposited in the respiratory tract, there are several transport pathways to clear them. The sooner particles are cleared from the lungs, the smaller the likelihood that pulmonary inflammation will develop. The most prevalent mechanism for solid particle clearance in the alveolar region is mediated by alveolar macrophages, through phagocytosis [52]. Once the macrophages have taken up particles, they move gradually toward the mucociliary escalator and are subsequently swallowed and cleared from the body through the gastrointestinal tract.
The retention time of particles in the lung depends on the deposition site and the interaction of particles with the inner lung surface. Particles that deposit in the conducting airways have a short retention time due to efficient mucociliary and cough clearance. The retention time increases when particles deposit deeper in the lungs, given the increased pathway length and decreased mucous velocity [59]. For microparticles, the retention half-time in the alveolar region is about 70 days in rats and up to 700 days in humans [52]. For nanoparticles, the retention half-time tends to be longer because they can deposit in the alveolar region when their (agglomerate) size is between 10 nm and 100 nm. Even with a short retention time and complete phagocytosis by alveolar macrophages, pulmonary inflammation may still occur, as macrophages are well known for the release of pro-inflammatory mediators in response to the uptake of nanoparticles [60,61].
If not cleared by phagocytosis, nanoparticles can reach pulmonary interstitial sites from which they are transported to the local lymph nodes. In addition, translocation of particles into the blood circulation can occur by crossing the lung barrier in the alveolar region [62]. Subsequently, the particles are cleared from the body by the liver, gastrointestinal tract, or kidneys. However, translocated particles may be able to reach organs beyond the lung, where they can accumulate, and might cause damage. When the deposition of particles in the lung overwhelms the clearance mechanisms of the lung, this may result in a retained lung burden or accumulation of particles in the lung, which is greater than expected from linear kinetics. This situation is called lung particle overload [7,63-66]. In rats, particle overload may result in sustained inflammation, fibrosis and induction of lung tumours, but the evidence on whether this situation occurs in humans is inconclusive [67].
For all these lung clearance and transport pathways, several nanomaterial characteristics are of influence.

Particle size

Size-dependent differences are important in the cascade of events leading to effective macrophage-mediated clearance. After deposition, agglomerates can disagglomerate into the primary particles [26,32], or primary particles can agglomerate after contact with the lung lining fluid [68]. At the site of deposition, the lung is thus exposed to large agglomerates, smaller agglomerates, or primary particles, as can be verified by transmission electron microscopy (TEM). Microparticles or large nanoparticle agglomerates, with a particle/agglomerate size of >;1 μm, are easy for macrophages to phagocytize [59], but single nanoparticles and small agglomerates are more difficult [69-71], and the smaller the nanoparticles, the less efficient their clearance [72]. Within 24 hours after exposure, alveolar macrophages phagocytize only 20% of nanoparticles compared to 80% of microparticles [52]. The nanoparticles that are not phagocytized are retained in the interstitium and in epithelial cells. Several in vivo inhalation studies report decreased clearance of nanoparticles from the lungs compared to larger-sized particles, resulting in increased retention time [32,69,70,73]. Increased retention gives nanoparticles the opportunity to translocate through the lung barrier. One study found low amounts (<;0.2% of the inhaled dose) of cerium oxide in secondary organs [27]. Another study reported no difference in clearance rate between 15 nm and 80 nm radio-labelled iridium particles in rats. However, the translocation of the 15 nm particles was higher compared to the 80 nm particles. Particles were found in secondary organs at fractions of <;0.002 and 0.001 of deposited dose of the smaller and larger particles, respectively [16]. This was confirmed in a follow-up study, in which translocation of 20 nm particles to secondary target organs was higher compared to 80 nm particles [17]. Another group found that translocation of gold nanoparticles of 2 nm, 40 nm, and 100 nm was very low, but greater for the 2 nm particles compared to the larger particles [34]. Similarly, after exposure to gold nanoparticles of 7 nm and 20 nm primary size (both having an agglomerate size of 45 nm), the 7 nm particles were more subject to translocation and more heavily distributed in secondary organs than the larger particles. However, the 20 nm particles were detected at higher levels in the aorta and faeces [26]. In contrast to these findings, when rats were exposed via inhalation to aluminum oxyhydroxide nanoparticles of 10 nm and 40 nm primary size (1.7 μm and 0.6 μm aerodynamic size), the translocation of the larger particles was higher compared to the smaller particles. The particles translocated to the lung-associated lymph nodes but were not detected in any other secondary organ [13]. The larger aerodynamic size of the 10 nm particles probably resulted in a lower deposited fraction in the alveoli compared to the 40 nm particles, which might explain the higher translocation rate of the 40 nm particles.
Overall, single nanoparticles and agglomerates of <;100 nm are less efficiently phagocytized by alveolar macrophages compared to microparticles or large agglomerates of >;1 μm [69,70,73]and less efficiently cleared by mucociliary clearance [71,72]. Increased retention of nanoparticles in the lung may damage the lungs or may result in the translocation of the nanoparticles to secondary organs. It is important to note that in general, clearance by translocation reported in the studies is very low, below 0.5% of the exposure concentration [16,17,27,34]. Over time, this may still accumulate to significant amounts for persistent nanoparticles, but no studies are available to demonstrate this.


Clearance from the lung is notably influenced by the shape of the particles [9]. Rigid fibres may more readily be entrapped in the lungs compared to spherical particles [74]. In rat inhalation studies, longer fibres appeared to be more difficult to clear than shorter ones [75]. Fibres longer than about 15–20 μm cannot be completely phagocytized by individual lung macrophages [76], resulting in frustrated phagocytosis in which adjacent cells attempt to phagocytize the same fibre[77]. In mice exposed to silver nanowires of different lengths via pharyngeal aspiration, shorter fibres with a length of 3, 5 and 10 μm could be completely phagocytized by alveolar macrophages whereas longer fibres with a length of 14 μm induced frustrated phagocytosis [39].
Exposure of mice to anatase titanium dioxide particles of various shapes (nanospheres, short nanobelts of 1 – 5 μm, and long nanobelts of 4 – 12 μm) resulted in a lung deposition of 135 μg both for the animals exposed to nanospheres and long nanobelts, but clearance was affected by particle shape. At 112 days after exposure, the lung burden was significantly lower in mice exposed to nanospheres (45 μg) than in those exposed to long nanobelts (60 μg) [38]. Nanoplatelets can also impair clearance compared to spherical nanoparticles. After intrapleural instillation in mice, graphene nanoplatelets induced prolonged retention in the pleural space whereas carbon black did not [40]. The study shows that the aerodynamic diameter of graphene nanoplatelets is much smaller than the projected area diameter, giving the platelets the opportunity to deposit in the alveoli [40]. In conclusion, long fibre-like or platelet nanoparticles are more readily entrapped in the lung and are more difficult to clear than shorter ones or spherical nanoparticles [38-40,76,77].

Chemical composition

Long-term exposure to diesel exhaust particles at concentrations of 0.8, 2.5, 4.5 and 7 mg/m3, carbon black at 11.6 mg/m3, and titanium dioxide (80% anatase, 20% rutile) at 10 mg/m3resulted in impaired clearance from the lungs for all three types. After 18 months of exposure and a recovery period of 3 months, lung clearance was still impaired and had not returned to normal levels. At that time point, the retained masses of the test materials were 47.7 mg/lung, 45.2 mg/lung and 37.8 mg/lung for diesel exhaust, carbon black and titanium dioxide, respectively. The strongest effect on lung clearance was caused by exposure to the highest concentration of diesel exhaust particles compared to similar concentrations of titanium dioxide and carbon black [21]. The effects after short-term inhalation of 5 days were tested for two types of titanium dioxide (anatase or 80% anatase with 20% rutile), zirconium dioxide, cerium dioxide, zinc oxide, silicon dioxide, carbon black, and multi-walled carbon nanotubes [22]. All nanoparticles were tested at concentrations of 0.5, 2.5 and 10 mg/m3, except for titanium dioxide nanoparticles that were tested at 2, 10 and 50 mg/m3 and multi-walled carbon nanotubes that were tested at 0.1, 0.5 and 2.5 mg/m3. Only exposure to anatase titanium dioxide, at the highest concentration tested, resulted in reduced lung clearance: the retained dose was 1635 μg directly after 5 days inhalation and 1340 μg at day 21–29 [22]. For the other nanoparticles tested, the retained doses in the lungs were at least a factor 4 lower, which might be explained by the lower exposure concentration.
Regarding translocation, the accumulation of carbon-iridium particles in secondary organs was lower compared to similar-sized iridium particles after inhalation [17]. When rats were exposed to either 30 nm iron oxide particles (8.5 mg/kw bw) or 20 nm zinc oxide particles (2.5 mg/kg bw), there were differences in translocation rate and distribution in the body. After 12 hours of exposure, zinc was detected in the liver, and after 36 hours, iron was detected in the liver and zinc was detected in the kidneys [23]. These measurements made no distinction between particles and ions, but can likely be explained by differences in dissolution rates. Overall, clearance and translocation rates differ depending on the chemical composition of the nanoparticles.

Surface charge

Surface charge of nanoparticles may also influence their translocation rate. Endogenous proteins like albumin adsorb to the surface of charged nanoparticles, thereby increasing their hydrodynamic size, altering their surface charge [78,79], and decreasing their surface reactivity and translocation rate [20]. The higher the surface charge density, the more proteins are adsorbed[80]. On the other hand, zwitterionic or neutral organic coatings prevent adsorption of serum proteins [81]. Examples are zwitterionic cysteine and polar PEG ligands that lead to rapid translocation of nanoparticles to the mediastinal lymph nodes [20]. Overall, charged particles attract proteins and thereby reduce their translocation rate [20,80,81]. In addition, the attracted proteins can form a corona around the nanoparticles and alter their recognition and uptake by alveolar macrophages.

Dissolution in physiological media

Many nanoparticles are insoluble and retain their physical shape after deposition. Others, like zinc oxide, copper oxide, nickel oxide, iron oxide, silicon dioxide, and silver nanoparticles can dissolve at various rates. The epithelium of the respiratory tract is covered with a lining fluid, and materials that dissolve in this fluid are readily transferred to the blood [82]. Only a few studies focused on the relation between particle dissolution and clearance from the lungs. One study suggests that after intratracheal instillation, the ability of metals to translocate from the lungs into the systemic circulation appears to be related to their solubility in water [83]. Another study showed that for cobalt oxide particles, the in vitro intracellular particle dissolution rate in alveolar macrophages was similar to the in vivo transfer to the blood [82]. However, when the released ions precipitate and/or transform, they might not be readily transferred and remain in the lungs. Therefore, the correlation between intracellular particle dissolution and in vivo clearance by transfer to the blood is only valid for specific particles of which the intracellular dissolution rate is the limiting step in their clearance [82]. After deposition, some particles will be taken up by alveolar macrophages. Phagolysosomes inside the macrophages contain proteolytic enzymes, oxygen radicals, chelators, precipitators, and a low pH of about 5, all of which may affect the engulfed particles. The low pH will increase particle dissolution. If particles release ions that destabilize the membrane of the lysosome, lysosomal content can leak and result in cell death, releasing the ions from the macrophages into the lungs. By affecting the barrier function of the lung epithelium, ions may enable intact nanoparticles to enter the bloodstream as well [82,84].

Pulmonary inflammation induced by nanomaterials

After deposition in the alveoli, nanoparticles interact with the alveolar epithelium. Nanoparticles can escape clearance by alveolar macrophages resulting in prolonged interaction with the alveolar epithelium [85]. At a high deposited dose of nanoparticles, there is epithelial injury, the immune system will treat the presence of the particles as a threat and inflammation ensues. As a response to the epithelial injury, there is an influx of neutrophils into the alveolar region [86-88]. The epithelial cells generate chemotactic factors that stimulate the migration of macrophages [89]. A prolonged exposure of epithelial cells to nanoparticles may result in hyper-secretion of chemo-attractants into the alveolar space. It is possible that this may disrupt the normal chemotactic gradient within the lung and result in particle-laden macrophages remaining within the respiratory region instead of migrating to the mucociliary escalator for clearance [90].
The effect of nanomaterials after inhalation that is reported most often is that of pulmonary inflammation, characterized by an influx of polymorphonuclear neutrophils, which may be transient or persistent [10-13,15,18,21-25,28-31,33,36-38,42-44]. At the cellular level, nanoparticle exposure can induce oxidative stress by the production of reactive oxygen species (ROS), which may be generated directly by particle structures in or near the cell or may arise more indirectly due to the effects of internalized particles on mitochondrial respiration [91] or the depletion of antioxidant species within the cell [92]. Oxidative stress can damage cells by peroxidising lipids, inducing inflammation, and altering proteins and DNA [93]. It can mediate a number of processes in the cells, such as apoptosis, DNA adduct formation, and pro-inflammatory gene expression [94]. All of these have been reported following exposure to some types and concentrations of nanoparticles [43,95-98]. Therefore, ROS production is considered the main underlying biochemical process in nanotoxicology, leading to inflammatory and other secondary processes that can ultimately cause cell damage and even cell death [93,99-101]. In the lung, persistent oxidative stress and inflammation after exposure to particulate matter are thought to cause fibrosis; in brain tissue, they are associated with neurodegenerative diseases [102,103].
The generation of ROS combined with proliferative signals at sites of persistent inflammation may also result in an accumulation of genetic defects. It is therefore important to determine which nanomaterial characteristics determine their persistence in the lung and their ability to cause inflammation. Figure 2 illustrates how nanoparticles can induce adverse effects at the cellular level. It should be noted that some of the mechanisms illustrated in Figure 2 are based on in vitro and (in vivo) studies that use extremely high and therefore unrealistic concentrations. These results provide evidence for the mechanism behind the observed toxicity. However, they should be evaluated using lower concentrations that resemble realistic inhalation exposure conditions. The mechanistic pathways that operate at low realistic doses might be different from those operating at very high doses when the organism’s defences are overwhelmed [52].
thumbnailFigure 2. Suggested mechanisms underlying nanoparticle-induced responses at the cellular level. At sufficiently high or persistent levels nanoparticle-induced responses potentially lead to altered tissue function and damage. Uptake of nanoparticles by alveolar macrophages can result in the release of mediators and oxidative stress, which may lead to mitochondrial damage, damage to lipids and DNA, and inflammation [104].

Particle size and surface area

Several in vivo studies compared the effect of particle size on pulmonary inflammation after inhalation or intratracheal instillation. Ultra-fine anatase titanium dioxide particles of 20 nm induced pulmonary inflammation after intratracheal instillation in rats and mice at lower mass concentrations compared to titanium dioxide particles of 250 nm [10]. Moreover, the onset of the inflammation was earlier in the 20 nm group. However, when the dose was expressed as surface area (measured by the method developed by Brunauer, Emmett, and Teller (BET) [105]), the dose–response curves overlapped [10], indicating that lung inflammation is determined by the total administered surface area. In another study, mice were intratracheally instilled with six types of carbon particles, with primary particle size ranging from 10 to 50 nm and specific surface area ranging from 30 to 800 m2/g [36]. Results indicated that particle surface area, measured by BET method, is the best dose metric for responses induced by carbonaceous nanoparticles [36]. In yet another study, however, the total surface area as measured by BET differed from the surface area calculated from particle size, resulting in different dose–response curves. The number of particles was thus considered a better dose metric to describe the effect of carbonaceous nanoparticles after inhalation, and not surface area [106]. These papers show that differences in measuring surface area of nanoparticles and differences in the analysis of experimental data can have a major influence on the results. Still, the studies show a clear effect of particle size in the induction of pulmonary inflammation, regardless if total surface area or particle number is the best dose metric to describe the effect.
Also in other studies, smaller particles caused more severe effects than larger particles when the same mass dose was administered. After intratracheal instillation at a concentration of 0.5 mg/ml, nano-sized nickel oxide particles induced lung inflammation and oxidative stress, but micro-sized nickel oxide particles did not [30]. In addition, several low-toxicity, low-solubility nanoparticles were tested in vivo by intratracheal instillation and in vitro on a human epithelial cell line. The data showed a clear relation between particle size and pulmonary inflammation as indicated by neutrophil influx and the induction of pro-inflammatory mediators; the smaller the particles, the greater the inflammatory response [107].
To investigate the difference in effect between primary particle size and agglomerate particle size, anatase titanium dioxide particles of diverse primary and agglomerate sizes were tested. When primary particles of three sizes were intratracheally instilled in the lungs of rats at 1.5 mg/kg bw, smaller particles induced greater inflammation in the short-term, but for all groups the inflammation was resolved after one week, regardless of particle size. When anatase titanium dioxide particles with the same primary size but different agglomerate size were tested at 5 mg/kg bw, no clear relationship was observed [31]. When rats were intratracheally instilled with 50 nm primary gold particles, their agglomerate of 200 nm, 250 nm primary gold particles, or their agglomerates of 770 nm, all four groups showed a mild inflammatory reaction at the tested concentration of 1.6 mg/kg bw. No differences were observed between single particles and their agglomerates [28]. However, when rats were exposed for 6 hours by inhalation to titanium dioxide particles with a primary size of 5 nm and an agglomerate size of 30 nm (small agglomerates) or 190 nm (large agglomerates), there was an effect of agglomerate size on pulmonary inflammation[18]. Exposures to both small and large agglomerates at 7 mg/m3 resulted in a lung burden of 51.3 and 51.5 μg, respectively and induced increased lactate dehydrogenase (LDH) and oxidative stress markers. Exposure to the large agglomerates significantly increased the number of neutrophils in the lungs, while exposure to the small agglomerates did not [18].
As discussed earlier, the agglomerate size of nanoparticles can change over time. In one study, primary particles of ultra-fine Teflon fume increased in size over time while the particle number decreased, indicating agglomeration. The airborne time allowed ‘aging,’ and after 3.5 minutes of aging, agglomerated Teflon particles exceeded 100 nm and no longer caused toxicity; only freshly generated fumes caused pulmonary inflammation [10].
Particles with a smaller primary size do not always induce more severe effects after inhalation than larger-sized particles in a similar dose. Ferric oxide particles of both 22 nm and 280 nm primary size induced dose-dependent pulmonary inflammation after intratracheal instillation of 0.8 and 20 mg/kg bw, and both sizes induced oxidative stress [37]. Aluminum oxyhydroxide particles of 10 nm and 40 nm primary size and 1.7 μm and 0.6 μm aerodynamic size both induced pulmonary inflammation after 4 weeks inhalation at the highest tested concentration (28 mg/m3exposed concentration, 1100 μg of 10 nm and 1800 μg of 40 nm internal dose in the lungs), with no differences due to particle size [13]. After exposure of mice to 50 μg nano-sized and micro-sized quartz particles by intratracheal instillation, pulmonary inflammation was induced in both groups, without differences due to particle size [33]. Similarly, cerium oxide particles of 5–10 nm (11 mg/m3), 40 nm (20 mg/m3) and <;5000 nm (55 mg/m3) primary size induced dose-dependent pulmonary inflammation to the same extent after 28 days of inhalation, perhaps because their aerodynamic particle size was similar, at 1.03 μm 1.17 μm and 1.40 μm, respectively [29].
Overall, the relation between particle size and pulmonary inflammation is not straightforward, suggesting that other parameters also drive the response. With application of similar mass doses of microparticles and nanoparticles, the latter have a higher total surface area and total particle number, which may result in increased pulmonary inflammation. As discussed earlier particles of different sizes differ in patterns of lung deposition and clearance, which influence the actual internal dose that might have an adverse effect on the lungs. For some particles with the same chemical composition and probably within a limited size range, deposited particle surface area seems to be a better predictor for inflammation than exposure concentrations [10,30,31,36,107].


The high aspect ratio of long, thin and rigid carbon nanotubes has raised concern that these carbon nanotubes may induce pulmonary responses similar to asbestos [108-110]. Carbon nanotubes that are of a curly and tangled nature rather than being straight fibres will probably not induce these pulmonary responses. Several studies indicate that multi-walled carbon nanotubes (MWCNT) can induce severe pulmonary inflammation, possibly because of their fibre-shape [41,65,111-114]. One group reported that high-aspect-ratio single-walled carbon nanotubes were 23-fold more inflammatory 1 day after aspiration in mice than an equal mass of spherical carbon black nanoparticles. As stated before, longer rigid fibres cannot be completely taken up by macrophages resulting in frustrated phagocytosis [39,77]. This can lead to an inflammatory response by continuous release of pro-inflammatory mediators, recruitment of inflammatory cells, and generation of reactive oxygen species. In addition, it might disrupt the normal process of motility in the lungs, leading to accumulation of longer fibres in the lower respiratory tract [53,77,115]. In one study, only long nanofibres and long asbestos fibres elicited sustained inflammation in the pleural space, with extensive lesion formation and fibrosis along the parietal pleura [77,116]. There is a cut-off value of 5 μm for long fibres to induce effects in the pleural space [77,117].
Besides fibres, other particle shapes can also influence the toxicity of nanoparticles. After pharyngeal aspiration in mice, at concentrations ranging from 1.88 to 30 μg, anatase titanium dioxide short nanobelts and long nanobelts induced dose- and time-dependent pulmonary inflammation while the nanospheres did not. In addition, there was some accumulation of long nanobelts in the interstitium suggesting increased interstitial access or impaired lymphatic clearance of particles with high aspect ratio [38]. Wire-shaped silver particles induced a strong toxicity at similar particle mass, surface area and number compared to spherical particles on human epithelial cells in vitro. In contrast, the various lengths of wire did not affect the level of toxicity [118]. These studies show that fibre-shaped, wire-shaped and nanobelt particles are more toxic to the lungs compared to spherical shaped nanoparticles [38,109,118].

Chemical composition

It is plausible that, similar to conventional chemicals, the chemical composition of nanomaterials can influence their effect after inhalation exposure. Nanoparticles consisting of relatively toxic materials such as nickel and cobalt induce severe inflammation, as they have a high surface-specific activity and a large surface area per unit mass [119,120]. Ferric oxide and zinc oxide nanoparticles induced serious hepatic lesions in rats when sprayed directly into the nose twice daily over three days at 8.5 and 2.5 mg/kg bw, respectively. In general, the liver lesions were more severe in animals treated with zinc oxide than those treated with iron oxide. Pulmonary inflammation and lesions were likewise evident in both exposure groups and tended to be more severe in the group exposed to iron oxide [23]. However, for both particle types, effects may have been caused at least in part by dissolved zinc or iron ions. In a long-term inhalation study, rats were exposed for 24 months and mice were exposed for 12 months to similar-sized aerodynamic particles of diesel exhaust at concentrations ranging from 0.8 to 7 mg/m3, carbon black at 11.6 mg/m3, or titanium dioxide at 10 mg/m3[21]. After 24 months exposure, the retained doses in the lungs of rats were 63.9 mg/lung, 43.9 mg/lung and 39.2 mg/lung for the highest exposed concentration of diesel exhaust, carbon black and titanium dioxide, respectively. Compared to controls, the mean lifetime of the rats was substantially shortened by exposure to carbon black and titanium dioxide, but not the diesel exhaust particles. Pulmonary inflammation and lesions were detected in all exposed animals. Particles of all three chemical compositions were detected in alveolar macrophages and in the alveolar region. After 6 months and 12 months of exposure, no lung tumours were found in the rats. After 24 months exposure and 6 months recovery, lung tumours were found in rats with all three exposures: 22% for diesel exhaust, 39% for carbon black, and 32% for titanium dioxide particles. It is remarkable that exposure to diesel exhaust resulted in the highest retained dose in the lungs but did not induce the highest tumour rate and did not shorten the lifetime of the rats. In mice, the tumour rate in the exposed groups did not differ from the controls [21].
After short-term inhalation of five days, differences were observed in the effects caused by nanoparticles of seven different chemical compositions [22]. All nanoparticles were tested at concentrations of 0.5, 2.5 and 10 mg/m3, except for titanium dioxide nanoparticles that were tested at 2, 10 and 50 mg/m3 and multi-walled carbon nanotubes that were tested at 0.1, 0.5 and 2.5 mg/m3. Of these, titanium dioxide, cerium dioxide, zinc oxide, and multi-walled carbon nanotubes induced dose-dependent pulmonary inflammation. For the first three, it was reversible at lower concentrations and partly reversible at the highest concentrations tested. The effects of multi-walled carbon nanotubes were irreversible and progressive. Exposure to zirconium dioxide, silicon dioxide, and carbon black induced no detectable inflammation at the tested concentrations. The nanoparticles that caused pulmonary inflammation were retained in the lungs at higher doses compared to the nanoparticles that did not induce pulmonary inflammation. After 5 days inhalation, the retained doses in the lungs were 1635 μg titanium dioxide, 340 μg cerium oxide, 428 μg zinc oxide compared to 200 μg zirconium dioxide, and 93 μg silicon dioxide, for the highest concentrations tested [22]. After intratracheal instillation at a concentration of 0.5 mg/ml, nano-sized nickel oxide particles induced lung inflammation and oxidative stress while nano-sized titanium dioxide particles did not [30]. It must be noted that titanium dioxide nanoparticles occur in different crystal structures: anatase, rutile or a combination of both. Several in vivo and in vitrostudies showed anatase titanium dioxide induced more adverse effects than rutile titanium dioxide[121-125]. According to these studies, chemical composition of the nanoparticles affects their potential to induce pulmonary inflammation, as would be expected from the different potency of conventional chemicals.

Surface charge

Nanoparticles have different surface charges depending on the coatings, surfactants, and solvents used in production. In addition, they may acquire a corona of proteins after deposition in the lung. The surface charge can be measured by the zeta-potential, which is the electric potential created between the charged groups associated with the surface of a particle and the suspension medium. The zeta-potential reveals dynamic changes depending on the pH of the medium and the adsorption of proteins that form the corona. In most metal oxide nanoparticles, the zeta-potential is negative in a neutral pH of 7.4, predominantly positive in an acidic environment of pH 5.6, and slightly negative when there is a corona of proteins or lung lining fluid [77]. When nanoparticles encounter biological fluids containing macromolecules, they attract the oppositely charged ones to form the corona. The surface charge will change based on the adsorption of those molecules and proteins, thereby reducing the overall charge of the nanoparticles [78,79]. When they are phagocytized by alveolar macrophages, the proteolytic enzymes and acidic pH in the phagolysosomes may strip off all or part of the corona and reveal the naked surface of the particle, restoring its original zeta-potential [126]. If the zeta-potential has a high positive value, the particle can bind to and damage membranes [77]. Positively charged nanoparticles are more easily taken up by lung cells, compared to neutral or negatively charged nanoparticles; they can thus remain in pulmonary cells for a long time, which may cause severe lung injury [20,127]. When nanoparticles with a high positive zeta-potential interact with the internal face of the lysosomal membrane, lysosomes can be destabilized, triggering cell death and inflammation[128,129]. Similarly, cationic nanoparticles are known to be more cytotoxic in vitro than neutral or anionic nanoparticles, causing lysosomal damage [19,130-132]. After intratracheal instillation of 15 metal and metal oxide nanoparticles in mice at a concentration of 150 cm2/rat, the ability of the particles to cause acute lung inflammation correlated linearly with their in vitro zeta-potential in an acidic environment [19]. For the low-solubility particles, zeta-potential correlated best with the induced pulmonary inflammation [19].
Overall, compared to neutral and negatively charged nanoparticles, positively charged nanoparticles can more easily be taken up by cells [20,127], leading ultimately to cell death and inflammation [128,129].

Dissolution in physiological media

Some nanoparticles can dissolve after deposition in the lungs, leading to formation of ions. When fast-dissolving nanoparticles are phagocytized by macrophages, the dissolution rate may be accelerated, leading to lysosomal destabilisation, cell death, and inflammation, dependent on the chemical identity of the ions that are released [84]. For fast-dissolving nanoparticles, the effect is mainly driven by their chemical composition [77]. Copper ions, zinc ions, and silver ions are known to have a toxic effect in vitro[42,130]. Mice were intratracheally instilled with a panel of 15 metal or metal oxide nanoparticles to relate their various physicochemical parameters to lung inflammation. Toxic ions, like copper and zinc caused destabilization of the lysosomal membrane[19]. In the acidic conditions of phagolysosomes, nanoparticles of copper oxide, magnesium oxide, and zinc oxide showed rapid, complete dissolution, while nanoparticles like silver, cerium oxide, silica, and titanium dioxide showed minimal dissolution [77]. The pulmonary toxicity of nickel, zinc, and copper oxide nanoparticles and their aqueous extracts (containing only ions and no particles) were investigated both in vitro and in vivo[43]. Results showed that the pulmonary inflammation induced by nickel oxide nanoparticles is caused by the particles and not by nickel ions in the aqueous extracts. For zinc oxide and copper oxide, the aqueous extracts induced effects similar to their corresponding nanoparticles in vitro. However, in vivo, zinc oxide and copper oxide nanoparticles caused particle-specific eosinophil recruitment that was not observed after administration of their aqueous extracts. In addition, exposure to the nickel and zinc oxide nanoparticles caused chronic effects that lasted up to four weeks. No aqueous extract caused such sustained inflammation, probably because soluble ions are rapidly cleared from the lungs.
It must be stressed that the dissolution rate of nanoparticles is not a constant factor but depends on particle size, coating, stability, manufacturing process, and biological environment. In vivo, released ions may be transported from the site of generation to other body parts, resulting in continued dissolution (and thus ion generation) of the residual nanoparticles. In vitro, dissolution may reach a maximum under static conditions. Especially for silver nanoparticles, the literature on their dissolution is contradictory. One study tested agglomeration, sedimentation, and dissolution of silver nanoparticles in biological media, finding that they did not dissolve in any of the tested fluids up to 96 hours incubation [133]. Other researchers report that silver nanoparticles indeed dissolve over time; the smaller the particles the faster they dissolve [134]. Whereas the effect of fast-dissolving nanoparticles probably depends on their chemical composition, the effects of slow- or partial-dissolving nanoparticles are more difficult to predict and will depend on the toxicity of the ions and of the particle that is retained [77].


Nanoparticles can be hydrophilic or hydrophobic, based mainly on their surface ligands, surfactants, or stabilizers [130]. Hydrophobic nanoparticles are difficult to disperse in biological fluids and media, while hydrophilic particles easily disperse. However, hydrophobicity enhances the penetration ability of nanoparticles into cell membranes and nuclear pores through the hydrophobic effect [93,135], which is the tendency of nonpolar substances to aggregate in aqueous solution and exclude water molecules [136]. To investigate the difference in effect between hydrophilic and hydrophobic nanoparticles, rats were exposed to three types of synthetic amorphous silica: 12 nm particles of hydrophilic pyrogenic silica, 12 nm particles of hydrophobic silica, and 18 nm particles of hydrophilic precipitated silica. After inhalation exposure for 13 weeks at 1, 6 and 30 mg/m3, the most pulmonary inflammation was induced in the group exposed to 12 nm hydrophilic silica, and the least inflammation in the group exposed to 18 nm hydrophilic silica. This is interesting, as both particle types had similar specific surface areas. It must be noted that the 12 nm hydrophilic silica dissolved quickly over time, which might have caused its inflammatory effects and subsequent fast clearance [25]. In a 5-day inhalation study of three types of synthetic amorphous silica at 1, 5 and 25 mg/m3, the pyrogenic silica (also known as fumed silica) induced the most pronounced pulmonary inflammation compared to silica gel and precipitated silica. The silica gel induced the least pulmonary inflammation. All three had a similar clearance rate [24]. Like the 13-week study, the 5-day study showed that hydrophilic pyrogenic silica particles induced more severe pulmonary inflammation compared to other forms of silica, indicating that surface hydrophobicity/hydrophilicity can influence the effect of nanomaterials after inhalation. However, other particle characteristics, such as solubility, charge, and aggregation may also play a role.

Surface reactivity

Chemical reactions and leakage of constituents occur at the surface of nanoparticles. The number of surface molecules increases exponentially when the particle decreases in diameter. Therefore, nanoparticles have a larger percentage of surface molecules compared to their ‘bulk’ counterparts[52,137]. Surface reactivity is the potency of particles to react with the immediate environment by inducing reactive oxygen species (ROS), leakage of constituents, and other biochemical reactions. It depends on the chemical composition, shape, size, solubility, and surface area of particles[96,138], and is generally determined by measuring the induction of ROS, as pulmonary inflammation is thought to be caused by ROS generation at the nanoparticle surface [93,99-101].
In a 5-day inhalation study, rats were exposed to 20–30 nm titanium dioxide (mixture of 70% anatase and 30% rutile) at a concentration of 88 mg/m3, pigmentary 200 nm titanium dioxide (rutile) at a concentration of 274 mg/m3, or quartz particles at a concentration of 96 mg/m3. The exposure resulted in a retained dose in the lungs of 2025 μg 20–30 nm titanium dioxide, 9182 μg 200 nm titanium dioxide, and 2190 μg quartz at the end of exposure. The two titanium dioxide particles differ in their crystallinity and surface area; the pigmentary titanium dioxide and the quartz particles differ in chemical composition and surface reactivity. All three particle types induced pulmonary inflammation, but it was reversible after 14 days for both types of titanium dioxide while being not reversible for the quartz. The recovery from effects seemed faster for the smaller titanium dioxide nanoparticles compared to the larger ones, which could reflect the higher mass lung burden of the larger particles caused by their higher exposure mass concentration. Overall, the quartz particles induced the most pulmonary inflammation despite their deposited surface area being the smallest. Therefore, the authors conclude that surface reactivity is more important than surface area in nanoparticle toxicity [44]. The same conclusion was reached when ultrafine titanium dioxide particles, differing in specific surface area and in surface reactivity, were tested in rats after intratracheal instillation at 1 and 5 mg/kg bw. Only the titanium dioxide particles with the highest surface reactivity induced pulmonary inflammation [11]. However, those that induced no pulmonary inflammation were reduced in reactivity by a coating of silica or alumina. This finding implies that the rats were exposed to particles with different chemical composition and that toxicity is determined by the composition of the surface that comes in contact with a cell. Similar findings were reported in another study in which various types of quartz particles were intratracheally instilled in rats at 1 and 5 mg/kg bw. The intensity of the resulting pulmonary inflammation was wide-ranging and not dependent on particle size; surface reactivity determined the toxicity of nanoparticles rather than particle size [12]. In vitro, quartz particles had a larger inflammatory potential compared to titanium dioxide and carbon black, although the quartz had a lower total surface area. The authors concluded that the greater ability of quartz to cause inflammation is related to its surface oxidative activity. For particles with a highly reactive surface like quartz, lower surface-area doses are required to induce pro-inflammatory responses[139].
Information on the surface reactivity of nanoparticles combines information on the effects of the chemical composition, shape, size, solubility, and surface area of the nanoparticles [96,138]. In addition, several studies found a correlation between surface reactivity and pulmonary inflammation [11,12,44]. Therefore, surface reactivity might be the most important nanoparticle characteristic determining their effect.

Methods to determine surface reactivity of nanomaterials

Several methods are available to determine surface reactivity of nanomaterials. As pulmonary inflammation is thought to be caused by the generation of ROS at the nanoparticle surface [93,99-101], this process has been studied in both cell-free and cellular conditions. The oxidation potential of nanoparticles in cell-free conditions can be easily analysed by electron spin resonance (ESR) techniques. These techniques use a spin-trapping agent to detect the nanoparticle-elicited generation of hydroxyl radicals in the presence of hydrogen peroxide. However, the process does not mimic the oxidation potential of the particles in the reducing environment of cells or extracellular fluid [96]. One study observed that the acellular potential of 20 nm silver nanoparticles to generate ROS was lower compared to larger silver nanoparticles, whereas its cellular potential was higher [140]. Another study observed that carbon black generated substantial amounts of ROS under cell-free conditions, but titanium dioxide nanoparticles did not. However, both showed a comparable dose-dependent capacity to produce intracellular ROS [141]. These results suggest that the generation of ROS might be an indirect effect of the interaction of the nanoparticles with cellular components. As it occurred in macrophages only at concentrations above those that reduce their metabolic activity, ROS generation may have been a secondary effect rather than causing the onset of cytotoxicity [140]. Therefore, the inability of nanoparticles to produce ROS in cell-free systems does not rule out their potential to produce intracellular oxidative stress [141]. Measuring the intracellular induction of ROS after nanoparticle exposure in vitro might be a way to categorize nanoparticles into hazard groups. However, there is no validated in vitro assay available to test all types of nanomaterials.
The intracellular induction of ROS can be measured using ESR techniques in combination with in vitro cellular exposure or using the 2’-7’-dichlorodihydrofluorecein diacetate (DCFH-DA) assay. The DCFH-DA assay uses a fluorescent probe to visualize the induction of ROS in cells after exposure to nanoparticles. Another method is the free radical analytical system (FRAS) assay that measures the formation of reactive oxygen metabolites (ROM) after exposure to nanoparticles. Besides measuring ROS generation, the surface reactivity of nanomaterials can be measured based on how well they serve the purpose for which they were designed. For example, some nanomaterials are added to a product for their catalytic potential, and others for their anti-bacterial activity or UV absorbance. For such nanomaterials, the surface reactivity required to catalyse reactions, kill bacteria, or absorb UV can be used to determine the actual surface reactivity of the materials. Other methods to measure surface reactivity are the erythrocyte haemolysis assay [142,143] and the vitamin C yellowing assay [11,144]. The erythrocyte haemolysis assay measures the amount of haemoglobin released after exposure of red blood cells to nanoparticles, and the vitamin C assay measures the chemical reactivity of nanoparticles toward an anti-oxidant. Neither of the assays can measure the surface reactivity of all types of nanomaterials.

Summary and conclusions

Although size has been put forward as an essential parameter to predict the pulmonary inflammation caused by nanomaterials, many other factors modulate the outcomes of toxicity studies. Our conclusions on the physicochemical characteristics of nanomaterials that affect pulmonary inflammation are listed below.
• The induction of pulmonary inflammation by nanomaterials depends largely on the extent of deposition in and clearance from the lungs.
• No single particle property can be identified as the most important in the induction of pulmonary inflammation by nanomaterials, as various properties affect different stages of the events leading to pulmonary inflammation.
• Surface reactivity might be the best predictor for a nanomaterial’s potential to induce pulmonary inflammation.
• There is a lack of information on the potential effects of long-term inhalation exposure to persistent nanomaterials, in terms of a potential delayed onset of pulmonary inflammation and translocation to secondary organs.
One essential step in predicting the risk of adverse human health outcomes based on experimental studies is to elucidate the deposition and clearance of nanomaterials. These processes are largely driven by the physical characteristics of nanoparticles and need to be taken into account when investigating to what extent specific nanomaterial characteristics affect pulmonary inflammation.
Agglomerate particle size and density are the most dominant of all the nanomaterial characteristics that affect lung deposition. Using these values as input, the dose of nanomaterials in the lung can quite accurately be predicted by the Multiple Pathway Particle Dosimetry model (MPPD model). However, it should be realized that other nanomaterial characteristics affecting lung deposition have not been investigated to the same extent, and results of the MPPD model should be interpreted with caution. Primary size, shape, chemical composition, charge, and dissolution rate can all affect clearance rate.
Many physicochemical characteristics of nanomaterials influence the severity of pulmonary inflammation, and no unifying metric can be identified based on the current available evidence. Some studies use rather high and unrealistic exposure concentrations, which might lead to lung particle overload conditions and severe adverse effects in laboratory animals, which will probably not occur under realistic in vivo exposure conditions in humans [67]. Results on the influence of primary particle size on pulmonary inflammation after inhalation are rather contradictory. Some studies report increased pulmonary inflammation after exposure to nanoparticles compared to larger micro-sized particles [10,30,31,36,107], while others report no difference [13,37]. As discussed earlier, both the agglomerate size and the primary size of particles affect lung deposition, clearance, and translocation. Therefore, inhalation studies should measure the actual deposition and retention of particles in the lung, preferably as total mass, surface area, and number dose. By comparing the effects of these local doses for the different particle sizes, conclusions can be drawn about the role of size in pulmonary inflammation. For some particles of the same chemical composition (and probably within a limited size range), the deposited surface area seems to be a better predictor for inflammation than mass exposure concentrations[10,30,31,36,107]. In addition, nanoparticles tend to agglomerate or even aggregate, changing particle size and available surface area. Information on the influence of particle agglomeration and aggregation on pulmonary inflammation is very limited.
Besides particle size, other nanoparticle characteristics influence deposition, clearance, and induction of pulmonary inflammation (Figure 3). All these characteristics affect different stages of the events leading to pulmonary inflammation; no single characteristic can be identified as the most important in the induction of pulmonary inflammation by nanomaterials.
thumbnailFigure 3. Nanomaterial characteristics resulting in increased lung deposition (in alveoli), impaired clearance rate, and the induction of pulmonary inflammation. The figure shows the physico-chemical characteristics of nanoparticles that result in 1) Increased lung deposition in the alveoli (left panel): Nanoparticles with a primary/agglomerate size of <;100 nm, or an agglomerate size between 100 nm and 1 μm with a high density, will deposit efficiently in the alveolar region. Non-hygroscopic nanoparticles will not grow in size by water uptake, resulting in a higher chance to reach the alveoli. 2) Impaired clearance rate (middle panel): Particles/agglomerates of <;100 nm are less efficiently phagocytised, nano-fibres and –platelets are less efficiently cleared compared to spheres, chemical composition influences clearance rate, charged nanoparticles attract proteins and reduce their clearance, and none or slowly dissolving nanoparticles are less efficiently cleared compared to fast dissolving nanoparticles. 3) The induction of pulmonary inflammation (right panel): After deposition of nanoparticles in the alveoli, the shown characteristics all influence the induction of pulmonary inflammation. Cationic particles are easily taken up by cells, fast dissolving nanoparticles can release toxic ions, and nanoparticles with a high surface reactivity can damage the lungs.
Measuring the surface reactivity of nanoparticles might be the best way to predict the toxicity of nanoparticles because it combines information on the effects of the chemical composition, shape, size, dissolution rate, and surface area of the particles [96,138]. A nanoparticle’s surface reactivity depends on the exposure medium, in which proteins or other macromolecules might attach to the surface of the nanoparticles. As nanomaterials can differ in all physicochemical characteristics, surface reactivity should be measured separately for each type of nanomaterial in the appropriate medium. Since there is no validated in vitro assay available to test all types of nanomaterials, a high-throughput in vitro assay should be developed and validated to determine the intracellular production of ROS after nanoparticle exposure. Still, animal studies are needed to validate the assays, as surface reactivity in vitro may differ from surface reactivity in vivo, when nanoparticles react with macromolecules in the body and where cellular concentrations are much lower.
If surface reactivity indeed turns out to be the best predictor for the toxicity of nanomaterials, it could be used to categorize nanomaterials into hazard groups. This might help reduce animal testing and speed up risk-assessment procedures, which are currently approached on a case-by-case basis. In addition, if a universal unit of surface reactivity can be defined, it can be included in the dose metric of nanomaterials. Still, while surface reactivity and the ability of nanomaterials to produce oxidative stress appear to be important predictors for toxicity in the lung, the effects of other nanomaterial characteristics should not be ruled out completely. Not all nanomaterial characteristics have been investigated to the same extent, and new types of nanomaterials are continuously being developed, taking on more complex forms that may be associated with new mechanisms of toxicity. A close collaboration between developers of nanomaterials and nanotoxicologists is necessary for the development of new nanomaterials with promising benefits and low risks.
Although very little is known on the exact clearance rates and retention of nanoparticles in the lungs, there is concern that non-soluble nanoparticles will be retained in the lungs and secondary organs for years. The phagocytosis of nanoparticles by macrophages is slower compared to microparticles [69,70,72], and nanoparticles deposit deeper in the lungs, where the clearance is slower due to increased pathway length and decreased mucous velocity [59]. A low-level but longer-lasting or repeated exposure might enable delayed or slowly developing pulmonary inflammation that is not resolved over time. Compared to larger particles, increased retention of nanoparticles may damage the lungs or may result in the translocation to secondary organs. It is important to note that in general, translocation to the systemic circulation is very low, below 0.5% of the exposure concentration [16,17,27,34]. It is not clear if there is a cut-off point in particle size beyond which particles can no longer translocate; under overload conditions, even larger particles might translocate.
Long-term animal studies are very expensive; therefore, there is a great need for alternative methods or new ways of combining information to predict long-term accumulation and effects of nanomaterials in the body. Even for short-term effects, not all characteristics can be studied in detail in animal studies, because the variation in nanomaterials is just too large. Therefore, alternative methods need to be developed for high-throughput screening of nanomaterials. Some co-culture in vitro systems have been developed that mimic the lung barrier [145-149] and hold promise for testing nanomaterials with diverse characteristics, although parallel in vivo studies to demonstrate their predictive value are often lacking. Finally, human epidemiological studies conducted in the workplace, for example, can provide useful information on the effects of nanomaterials after inhalation.
Since no single nanoparticle property can be identified as the most important in the induction of pulmonary inflammation, we have some recommendations for future research listed below. The ultimate goal is to categorize nanomaterials according to their characteristics, which would be of immense value for the risk assessment of these wide-ranging and fast-developing products.
• The impact of a nanomaterial characteristic should be systematically tested in different experimental setups by using a number of different nanomaterials, varying only in a single physicochemical characteristic e.g. surface reactivity, and analysed by controlling for other variables such as size and chemistry.
• Surface reactivity should be investigated as a valuable predictor for a nanomaterial’s potential to induce pulmonary inflammation.
• The data from studies that systematically tested a single nanomaterial characteristic can be combined into a large data set to carry out multivariate analysis to determine potential combinations of characteristics that are important in affecting pulmonary inflammation.
• Agglomerate particle size should be measured as closely as possible to the site of exposure in animal studies or in occupational exposure settings in order to accurately predict the lung deposition by the particle dosimetry models such as the MPPD model.
• Nanomaterial characteristics should be measured in the appropriate medium, because reaction with macromolecules in biological fluids will change nanoparticle characteristics and thereby their cellular uptake and effect.
• There is a need to generate data on biodistribution and accumulation of nanomaterials upon long-term exposure, as well as the induction of toxic effects, to assess which of the physicochemical properties have the largest influence on delayed or chronic pulmonary inflammation.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HB drafted the manuscript. MP and FRC contributed to the concept and design of the manuscript. MP, FRC, IG and WHdeJ have been involved in revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.


This work was supported by the project ‘Integrated Risk Assessment of Nanomaterials’ from the National Institute for Public Health and the Environment; by the NanoNextNL program ‘Risk Analysis and Technology Assessment: Human Health Risks,’ and the Netherlands Food and Consumer Product Safety Authority.
Prof. Dr. Henk van Loveren, Dr. Agnes Oomen, and Dr. Eric Bleeker are acknowledged for critical review of the manuscript. Lucy Phillips is acknowledged for editorial review of the manuscript.


  1. Nanotechnologies PE: Consumer Products Inventory. Retrieved [January, 2013]. webcite
  2. Maynard AD, Kuempel ED: Airborne nanostructured particles and occupational health.
    J Nanoparticle Res 2005, 7:587-614. Publisher Full Text OpenURL
  3. Christensen FM, Johnston HJ, Stone V, Aitken RJ, Hankin S, Peters S, Aschberger K: Nano-silver - feasibility and challenges for human health risk assessment based on open literature.
    Nanotoxicology 2010, 4:284-295. PubMed Abstract | Publisher Full Text OpenURL
  4. Oomen AG, Bennink M, Engelen JGM, Sips AJAM: Nanomaterial in consumer products: Detection, characterisation and interpretation.
    RIVM Report 320029001 2011., 96 OpenURL
  5. Wijnhoven SWP, Dekkers S, Kooi M, Jongeneel R, Jong WH: Nanomaterials in consumer products: Update of products on the European market in 2010.
    RIVM Report 340370003 2011., 78 OpenURL
  6. Ji JH, Jung JH, Kim SS, Yoon JU, Park JD, Choi BS, Chung YH, Kwon IH, Jeong J, Han BS, Shin JH, Sung JH, Song KS, Yu IJ: Twenty-eight-day inhalation toxicity study of silver nanoparticles in Sprague–Dawley rats.
    Inhal Toxicol 2007, 19:857-871. PubMed Abstract | Publisher Full Text OpenURL
  7. Pauluhn J: Poorly soluble particulates: searching for a unifying denominator of nanoparticles and fine particles for DNEL estimation.
    Toxicology 2011, 279:176-188. PubMed Abstract | Publisher Full Text OpenURL
  8. Sung JH, Ji JH, Park JD, Yoon JU, Kim DS, Jeon KS, Song MY, Jeong J, Han BS, Han JH, Chung YH, Chang HK, Lee JH, Cho MH, Kelman BJ, Yu IJ: Subchronic inhalation toxicity of silver nanoparticles.
    Toxicol Sci 2009, 108:452-461. PubMed Abstract | Publisher Full Text OpenURL
  9. Yang W, Peters JI, Williams RO 3rd: Inhaled nanoparticles–a current review.
    Int J Pharm 2008, 356:239-247. PubMed Abstract | Publisher Full Text OpenURL
  10. Oberdorster G, Finkelstein JN, Johnston C, Gelein R, Cox C, Baggs R, Elder AC: Acute pulmonary effects of ultrafine particles in rats and mice.
    Res Rep Health Eff Inst 2000, 2000:5-74.
    disc 75–86
  11. Warheit DB, Webb TR, Reed KL, Frerichs S, Sayes CM: Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties.
    Toxicology 2007, 230:90-104. PubMed Abstract | Publisher Full Text OpenURL
  12. Warheit DB, Webb TR, Colvin VL, Reed KL, Sayes CM: Pulmonary bioassay studies with nanoscale and fine-quartz particles in rats: toxicity is not dependent upon particle size but on surface characteristics.
    Toxicol Sci 2007, 95:270-280. PubMed Abstract | Publisher Full Text OpenURL
  13. Pauluhn J: Pulmonary toxicity and fate of agglomerated 10 and 40 nm aluminum oxyhydroxides following 4-week inhalation exposure of rats: toxic effects are determined by agglomerated, not primary particle size.
    Toxicol Sci 2009, 109:152-167. PubMed Abstract | Publisher Full Text OpenURL
  14. de Jong W, Bridges J, Dawson K, Jung T, Proykova A, (SCENIHR) SCoEaNIHR: Scientific Basis for the Definition of the Term ‘nanomaterial’. Belgium: European Commission, Brussels; 2010:46. OpenURL
  15. Ho M, Wu KY, Chein HM, Chen LC, Cheng TJ: Pulmonary toxicity of inhaled nanoscale and fine zinc oxide particles: mass and surface area as an exposure metric.
    Inhal Toxicol 2011, 23:947-956. PubMed Abstract | Publisher Full Text OpenURL
  16. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdorster G, Ziesenis A: Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low.
    J Toxicol Environ Health A 2002, 65:1513-1530. PubMed Abstract | Publisher Full Text OpenURL
  17. Kreyling WG, Semmler-Behnke M, Seitz J, Scymczak W, Wenk A, Mayer P, Takenaka S, Oberdorster G: Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lung of rats to the blood and secondary target organs.
    Inhal Toxicol 2009, 21(Suppl 1):55-60. OpenURL
  18. Noel A, Maghni K, Cloutier Y, Dion C, Wilkinson KJ, Halle S, Tardif R, Truchon G: Effects of inhaled nano-TiO2 aerosols showing two distinct agglomeration states on rat lungs.
    Toxicol Lett 2012, 214:109-119. PubMed Abstract | Publisher Full Text OpenURL
  19. Cho WS, Duffin R, Thielbeer F, Bradley M, Megson IL, Macnee W, Poland CA, Tran CL, Donaldson K: Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
    Toxicol Sci 2012, 126:469-477. PubMed Abstract | Publisher Full Text OpenURL
  20. Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A: Rapid translocation of nanoparticles from the lung airspaces to the body.
    Nat Biotechnol 2010, 28:1300-1303. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  21. Heinrich U, Fuhst R, Rittinghausen S, Creutzenberg O, Bellmann B, Koch W, Levsen K:Chronic inhalation exposure of Wistar rats and two different strains of mice to diesel exhaust, carbon black and titanium dioxide.
    Inhal Toxicol 1995, 7:23. OpenURL
  22. Landsiedel R, Ma-Hock L, Kroll A, Hahn D, Schnekenburger J, Wiench K, Wohlleben W:Testing metal-oxide nanomaterials for human safety.
    Adv Mater 2010, 22:2601-2627. PubMed Abstract | Publisher Full Text OpenURL
  23. Wang L, Ding W, Zhang F: Acute toxicity of ferric oxide and zinc oxide nanoparticles in rats.
    J Nanosci Nanotechnol 2010, 10:8617-8624. PubMed Abstract | Publisher Full Text OpenURL
  24. Arts JH, Muijser H, Duistermaat E, Junker K, Kuper CF: Five-day inhalation toxicity study of three types of synthetic amorphous silicas in Wistar rats and post-exposure evaluations for up to 3 months.
    Food Chem Toxicol 2007, 45:1856-1867. PubMed Abstract | Publisher Full Text OpenURL
  25. Reuzel PG, Bruijntjes JP, Feron VJ, Woutersen RA: Subchronic inhalation toxicity of amorphous silicas and quartz dust in rats.
    Food Chem Toxicol 1991, 29:341-354. PubMed Abstract | Publisher Full Text OpenURL
  26. Balasubramanian SK, Poh KW, Ong CN, Kreyling WG, Ong WY, Yu LE: The effect of primary particle size on biodistribution of inhaled gold nano-agglomerates.
    Biomaterials 2013, 34:5439-5452. PubMed Abstract | Publisher Full Text OpenURL
  27. Geraets L, Oomen AG, Schroeter JD, Coleman VA, Cassee FR: Tissue distribution of inhaled micro- and nano-sized cerium oxide particles in rats: results from a 28-day exposure study.
    Toxicol Sci 2012, 127:463-473. PubMed Abstract | Publisher Full Text OpenURL
  28. Gosens I, Post JA, de la Fonteyne LJ, Jansen EH, Geus JW, Cassee FR, de Jong WH: Impact of agglomeration state of nano- and submicron sized gold particles on pulmonary inflammation.
  29. Gosens I, Mathijssen LE, Bokkers BG, Muijser H, Cassee FR: Comparative hazard identification of nano- and micro-sized cerium oxide particles based on 28-day inhalation studies in rats.
    Nanotoxicology 2014, 8:643-653. PubMed Abstract | Publisher Full Text OpenURL
  30. Horie M, Fukui H, Endoh S, Maru J, Miyauchi A, Shichiri M, Fujita K, Niki E, Hagihara Y, Yoshida Y, Morimoto Y, Iwahashi H: Comparison of acute oxidative stress on rat lung induced by nano and fine-scale, soluble and insoluble metal oxide particles: NiO and TiO2.
    Inhal Toxicol 2012, 24:391-400. PubMed Abstract | Publisher Full Text OpenURL
  31. Kobayashi N, Naya M, Endoh S, Maru J, Yamamoto K, Nakanishi J: Comparative pulmonary toxicity study of nano-TiO(2) particles of different sizes and agglomerations in rats: different short- and long-term post-instillation results.
    Toxicology 2009, 264:110-118. PubMed Abstract | Publisher Full Text OpenURL
  32. Oberdorster G, Ferin J, Lehnert BE: Correlation between particle size, in vivo particle persistence, and lung injury.
    Environ Health Perspect 1994, 102(Suppl 5):173-179. Publisher Full Text OpenURL
  33. Roursgaard M, Poulsen SS, Poulsen LK, Hammer M, Jensen KA, Utsunomiya S, Ewing RC, Balic-Zunic T, Nielsen GD, Larsen ST: Time-response relationship of nano and micro particle induced lung inflammation. Quartz as reference compound.
    Hum Exp Toxicol 2010, 29:915-933. PubMed Abstract | Publisher Full Text OpenURL
  34. Sadauskas E, Jacobsen NR, Danscher G, Stoltenberg M, Vogel U, Larsen A, Kreyling W, Wallin H: Biodistribution of gold nanoparticles in mouse lung following intratracheal instillation.
  35. Sayes CM, Reed KL, Glover KP, Swain KA, Ostraat ML, Donner EM, Warheit DB: Changing the dose metric for inhalation toxicity studies: short-term study in rats with engineered aerosolized amorphous silica nanoparticles.
    Inhal Toxicol 2010, 22:348-354. PubMed Abstract | Publisher Full Text OpenURL
  36. Stoeger T, Reinhard C, Takenaka S, Schroeppel A, Karg E, Ritter B, Heyder J, Schulz H:Instillation of six different ultrafine carbon particles indicates a surface area threshold dose for acute lung inflammation in mice.
    Environ Health Perspect 2006, 114:328-333. PubMed Abstract | PubMed Central Full Text OpenURL
  37. Zhu MT, Feng WY, Wang B, Wang TC, Gu YQ, Wang M, Wang Y, Ouyang H, Zhao YL, Chai ZF: Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats.
    Toxicology 2008, 247:102-111. PubMed Abstract | Publisher Full Text OpenURL
  38. Porter DW, Wu N, Hubbs A, Mercer R, Funk K, Meng F, Li J, Wolfarth M, Battelli L, Friend S, Andrew M, Hamilton R, Sriram K, Yang F, Castranova V, Holian A: Differential Mouse Pulmonary Dose- and Time Course-Responses to Titanium Dioxide Nanospheres and Nanobelts.
    Toxicol Sci 2013, 131:179-193. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  39. Schinwald A, Chernova T, Donaldson K: Use of silver nanowires to determine thresholds for fibre length-dependent pulmonary inflammation and inhibition of macrophage migration in vitro.
  40. Schinwald A, Murphy FA, Jones A, MacNee W, Donaldson K: Graphene-based nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties.
    ACS Nano 2012, 6:736-746. PubMed Abstract | Publisher Full Text OpenURL
  41. Ma-Hock L, Strauss V, Treumann S, Kuttler K, Wohlleben W, Hofmann T, Groters S, Wiench K, van Ravenzwaay B, Landsiedel R: Comparative inhalation toxicity of multi-wall carbon nanotubes, graphene, graphite nanoplatelets and low surface carbon black.
  42. Cho WS, Duffin R, Howie SE, Scotton CJ, Wallace WA, Macnee W, Bradley M, Megson IL, Donaldson K: Progressive severe lung injury by zinc oxide nanoparticles; the role of Zn2+ dissolution inside lysosomes.
  43. Cho WS, Duffin R, Poland CA, Duschl A, Oostingh GJ, Macnee W, Bradley M, Megson IL, Donaldson K: Differential pro-inflammatory effects of metal oxide nanoparticles and their soluble ions in vitro and in vivo; zinc and copper nanoparticles, but not their ions, recruit eosinophils to the lungs.
    Nanotoxicology 2012, 6:22-35. PubMed Abstract | Publisher Full Text OpenURL
  44. van Ravenzwaay B, Landsiedel R, Fabian E, Burkhardt S, Strauss V, Ma-Hock L:Comparing fate and effects of three particles of different surface properties: nano-TiO(2), pigmentary TiO(2) and quartz.
    Toxicol Lett 2009, 186:152-159. PubMed Abstract | Publisher Full Text OpenURL
  45. ICRP: Human respiratory tract model for radiological protectionVolume 24. Canada: ICRP Publication 66; 1994::1-3. [International Commission on Radiological ProtectionOpenURL
  46. Asgharian B, Price O, Miller F, Subramaniam R, Cassee FR, Freijer J, van Bree L, Winter-Sorkina R: Multiple-Path Particle Dosimetry Model (MPPD v 2.11): A Model for Human and Rat Airway Particle Dosimetry. Raleigh, North Carolina, USA: Copyright by Applied Research Associates (ARA); 2009. [Applied Research Associates (ARA), Hamner Institutes for Health Sciences, National Institute for Public Health and the Environment (RIVM), and Ministry of Housing, Spatial Planning and the EnvironmentOpenURL
  47. Carvalho TC, Peters JI, Williams RO 3rd: Influence of particle size on regional lung deposition–what evidence is there?
    Int J Pharm 2011, 406:1-10. PubMed Abstract | Publisher Full Text OpenURL
  48. Veranth JM, Ghandehari H, Grainger DW: Nanoparticles in the Lung.
    Comprehensive Toxicology 2010, 453-475. OpenURL
  49. Tritscher T, Zerrath AF, Elzey S, Han HS: Data Merging of Size Distributions from Electrical Mobility and Optical Measurements. Aachen, Germany: TSI GmbH, Particle Instruments; 2013:1. OpenURL
  50. Khlystov A, Stanier C, Pandis SN: An algorithm for combining electrical mobility and aerodynamic size distributions data when measuring ambient aerosol.
    Aerosol Science and Technology 2004, 229-238. OpenURL
  51. Cassee FR, Muijser H, Duistermaat E, Freijer JJ, Geerse KB, Marijnissen JC, Arts JH:Particle size-dependent total mass deposition in lungs determines inhalation toxicity of cadmium chloride aerosols in rats. Application of a multiple path dosimetry model.
    Arch Toxicol 2002, 76:277-286. PubMed Abstract | Publisher Full Text OpenURL
  52. Oberdorster G, Oberdorster E, Oberdorster J: Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.
    Environ Health Perspect 2005, 113:823-839. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  53. Donaldson K, Murphy FA, Duffin R, Poland CA: Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma.
  54. Sanchez VC, Jachak A, Hurt RH, Kane AB: Biological interactions of graphene-family nanomaterials: an interdisciplinary review.
    Chem Res Toxicol 2012, 25:15-34. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  55. Oberdorster G: Dosimetric principles for extrapolating results of rat inhalation studies to humans, using an inhaled Ni compound as an example.
    Health Phys 1989, 57(1):213-220. PubMed Abstract OpenURL
  56. Hinds WC: Chapter 12. In Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles. New York: John Wiley & Sons; 1982. OpenURL
  57. Kreyling WG: Coagulation kinetics of 30 nm nanoparticles aerosol. München: Personal Communication; 2013. OpenURL
  58. Varghese SK, Gangamma S: Particle deposition in human respiratory system: deposition of concentrated hygroscopic aerosols.
    Inhal Toxicol 2009, 21:619-630. PubMed Abstract | Publisher Full Text OpenURL
  59. Geiser M, Kreyling WG: Deposition and biokinetics of inhaled nanoparticles.
  60. Napierska D, Thomassen LC, Vanaudenaerde B, Luyts K, Lison D, Martens JA, Nemery B, Hoet PH: Cytokine production by co-cultures exposed to monodisperse amorphous silica nanoparticles: the role of size and surface area.
    Toxicol Lett 2012, 211:98-104. PubMed Abstract | Publisher Full Text OpenURL
  61. Roberts JR, Chapman RS, Tirumala VR, Karim A, Chen BT, Schwegler-Berry D, Stefaniak AB, Leonard SS, Antonini JM: Toxicological evaluation of lung responses after intratracheal exposure to non-dispersed titanium dioxide nanorods.
    J Toxicol Environ Health A 2011, 74:790-810. PubMed Abstract | Publisher Full Text OpenURL
  62. Borm PJ, Robbins D, Haubold S, Kuhlbusch T, Fissan H, Donaldson K, Schins R, Stone V, Kreyling W, Lademann J, Krutmann J, Warheit D, Oberdorster E: The potential risks of nanomaterials: a review carried out for ECETOC.
  63. Morrow PE: Possible mechanisms to explain dust overloading of the lungs.
    Fundam Appl Toxicol 1988, 10:369-384. PubMed Abstract | Publisher Full Text OpenURL
  64. Morrow PE: Dust overloading of the lungs: update and appraisal.
    Toxicol Appl Pharmacol 1992, 113:1-12. PubMed Abstract | Publisher Full Text OpenURL
  65. Pauluhn J: Subchronic 13-week inhalation exposure of rats to multiwalled carbon nanotubes: toxic effects are determined by density of agglomerate structures, not fibrillar structures.
    Toxicol Sci 2010, 113:226-242. PubMed Abstract | Publisher Full Text OpenURL
  66. Pauluhn J: Retrospective analysis of 4-week inhalation studies in rats with focus on fate and pulmonary toxicity of two nanosized aluminum oxyhydroxides (boehmite) and pigment-grade iron oxide (magnetite): the key metric of dose is particle mass and not particle surface area.
    Toxicology 2009, 259:140-148. PubMed Abstract | Publisher Full Text OpenURL
  67. ILSI: The relevance of the rat lung response to particle overload for human risk assessment: a workshop consensus report. ILSI Risk Science Institute Workshop Participants.
    Inhal Toxicol 2000, 12:1-17. OpenURL
  68. Creutzenberg O, Bellmann B, Korolewitz R, Koch W, Mangelsdorf I, Tillmann T, Schaudien D: Change in agglomeration status and toxicokinetic fate of various nanoparticles in vivo following lung exposure in rats.
    Inhal Toxicol 2012, 24:821-830. PubMed Abstract | Publisher Full Text OpenURL
  69. Bakand S, Hayes A, Dechsakulthorn F: Nanoparticles: a review of particle toxicology following inhalation exposure.
    Inhal Toxicol 2012, 24:125-135. PubMed Abstract | Publisher Full Text OpenURL
  70. Muhlfeld C, Gehr P, Rothen-Rutishauser B: Translocation and cellular entering mechanisms of nanoparticles in the respiratory tract.
    Swiss Med Wkly 2008, 138:387-391. PubMed Abstract OpenURL
  71. Geiser M: Update on macrophage clearance of inhaled micro- and nanoparticles.
    J Aerosol Med Pulm Drug Deliv 2010, 23:207-217. PubMed Abstract | Publisher Full Text OpenURL
  72. Geiser M, Casaulta M, Kupferschmid B, Schulz H, Semmler-Behnke M, Kreyling W: The role of macrophages in the clearance of inhaled ultrafine titanium dioxide particles.
    Am J Respir Cell Mol Biol 2008, 38:371-376. PubMed Abstract | Publisher Full Text OpenURL
  73. Phalen RF, Mendez LB, Oldham MJ: New developments in aerosol dosimetry.
    Inhal Toxicol 2010, 22(Suppl 2):6-14. PubMed Abstract | Publisher Full Text OpenURL
  74. Vincent JH, Johnston AM, Jones AD, Bolton RE, Addison J: Kinetics of deposition and clearance of inhaled mineral dusts during chronic exposure.
    Br J Ind Med 1985, 42:707-715. PubMed Abstract | PubMed Central Full Text OpenURL
  75. Morgan A, Talbot RJ, Holmes A: Significance of fibre length in the clearance of asbestos fibres from the lung.
    Br J Ind Med 1978, 35:146-153. PubMed Abstract | PubMed Central Full Text OpenURL
  76. McClellan RO, Henderson RF: Concepts in Inhalation Toxicology. Washington: Taylor & Francis; 1995:648. OpenURL
  77. Donaldson K, Schinwald A, Murphy F, Cho WS, Duffin R, Tran L, Poland C: The Biologically Effective Dose in Inhalation Nanotoxicology.
    Acc Chem Res 2013, 46:723-732. PubMed Abstract | Publisher Full Text OpenURL
  78. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA: Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts.
    Proc Natl Acad Sci U S A 2008, 105:14265-14270. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  79. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, Sioutas C, Yeh JI, Wiesner MR, Nel AE: Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm.
    Nano Lett 2006, 6:1794-1807. PubMed Abstract | Publisher Full Text OpenURL
  80. Gessner A, Lieske A, Paulke B, Muller R: Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis.
    Eur J Pharm Biopharm 2002, 54:165-170. PubMed Abstract | Publisher Full Text OpenURL
  81. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV: Renal clearance of quantum dots.
    Nat Biotechnol 2007, 25:1165-1170. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  82. Kreyling WG: Intracellular particle dissolution in alveolar macrophages.
    Environ Health Perspect 1992, 97:121-126. PubMed Abstract | PubMed Central Full Text OpenURL
  83. Wallenborn JG, McGee JK, Schladweiler MC, Ledbetter AD, Kodavanti UP: Systemic translocation of particulate matter-associated metals following a single intratracheal instillation in rats.
    Toxicol Sci 2007, 98:231-239. PubMed Abstract | Publisher Full Text OpenURL
  84. Koch W, Stober W: A simple pulmonary retention model accounting for dissolution and macrophage-mediated removal of deposited polydisperse particles.
    Inhal Toxicol 2001, 13:129-148. PubMed Abstract | Publisher Full Text OpenURL
  85. Maynard RL, Donaldson K, Tetley TD: Type 1 pulmonary epithelial cells: a new compartment involved in the slow phase of particle clearance from alveoli.
    Nanotoxicology 2013, 7:350-351. PubMed Abstract | Publisher Full Text OpenURL
  86. Aarbiou J, Ertmann M, van Wetering S, van Noort P, Rook D, Rabe KF, Litvinov SV, van Krieken JH, de Boer WI, Hiemstra PS: Human neutrophil defensins induce lung epithelial cell proliferation in vitro.
    J Leukoc Biol 2002, 72:167-174. PubMed Abstract | Publisher Full Text OpenURL
  87. Zhou X, Dai Q, Huang X: Neutrophils in acute lung injury.
    Front Biosci (Landmark Ed) 2012, 17:2278-2283. PubMed Abstract | Publisher Full Text OpenURL
  88. Nicod LP: Pulmonary defence mechanisms.
    Respiration 1999, 66:2-11. PubMed Abstract | Publisher Full Text OpenURL
  89. Barlow PG, Clouter-Baker A, Donaldson K, Maccallum J, Stone V: Carbon black nanoparticles induce type II epithelial cells to release chemotaxins for alveolar macrophages.
  90. Donaldson K, Borm PJ: Interactions between macrophages and epithelial cells.
    In Particle Toxicology Edited by Press C. 2006, 190. OpenURL
  91. Xia T, Kovochich M, Liong M, Zink JI, Nel AE: Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways.
    ACS Nano 2008, 2:85-96. PubMed Abstract | Publisher Full Text OpenURL
  92. Park EJ, Yi J, Chung KH, Ryu DY, Choi J, Park K: Oxidative stress and apoptosis induced by titanium dioxide nanoparticles in cultured BEAS-2B cells.
    Toxicol Lett 2008, 180:222-229. PubMed Abstract | Publisher Full Text OpenURL
  93. Cheng LC, Jiang X, Wang J, Chen C, Liu RS: Nano-bio effects: interaction of nanomaterials with cells.
    Nanoscale 2013, 5:3547-3569. PubMed Abstract | Publisher Full Text OpenURL
  94. Donaldson K, Poland CA: Inhaled nanoparticles and lung cancer - what we can learn from conventional particle toxicology.
    Swiss Med Wkly 2012, 142:w13547. PubMed Abstract OpenURL
  95. Donaldson K, Poland CA, Schins RP: Possible genotoxic mechanisms of nanoparticles: criteria for improved test strategies.
    Nanotoxicology 2010, 4:414-420. PubMed Abstract | Publisher Full Text OpenURL
  96. Moller P, Jacobsen NR, Folkmann JK, Danielsen PH, Mikkelsen L, Hemmingsen JG, Vesterdal LK, Forchhammer L, Wallin H, Loft S: Role of oxidative damage in toxicity of particulates.
    Free Radic Res 2010, 44:1-46. PubMed Abstract | Publisher Full Text OpenURL
  97. Li N, Xia T, Nel AE: The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles.
    Free Radic Biol Med 2008, 44:1689-1699. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  98. Landsiedel R, Kapp MD, Schulz M, Wiench K, Oesch F: Genotoxicity investigations on nanomaterials: methods, preparation and characterization of test material, potential artifacts and limitations–many questions, some answers.
    Mutat Res 2009, 681:241-258. PubMed Abstract | Publisher Full Text OpenURL
  99. Elsaesser A, Howard CV: Toxicology of nanoparticles.
    Adv Drug Deliv Rev 2012, 64:129-137. PubMed Abstract | Publisher Full Text OpenURL
  100. Nel A, Xia T, Madler L, Li N: Toxic potential of materials at the nanolevel.
    Science 2006, 311:622-627. PubMed Abstract | Publisher Full Text OpenURL
  101. Muhlfeld C, Rothen-Rutishauser B, Blank F, Vanhecke D, Ochs M, Gehr P: Interactions of nanoparticles with pulmonary structures and cellular responses.
    Am J Physiol Lung Cell Mol Physiol 2008, 294:L817-L829. PubMed Abstract |Publisher Full Text OpenURL
  102. Brook RD, Rajagopalan S, Pope CA 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC Jr, Whitsel L, Kaufman JD: Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from the American Heart Association.
    Circulation 2010, 121:2331-2378. PubMed Abstract | Publisher Full Text OpenURL
  103. Simko M, Mattsson MO: Risks from accidental exposures to engineered nanoparticles and neurological health effects: a critical review.
  104. Colognato R, Park MVDZ, Wick P, De Jong WH: Interactions with the Human Body. InAdverse Effects of Engineered Nanomaterials: Exposure, Toxicology and Impact on Human Health. Edited by Fadeel B, Pietroiusti A, Shvedova AA. Amsterdam: Elsevier; 2012. OpenURL
  105. Brunauer S, Emmett PH, Teller E: Absorption of gases in multimolecular layers.
    J Am Chem Soc 1938, 60:309-319. Publisher Full Text OpenURL
  106. Wittmaack K: In search of the most relevant parameter for quantifying lung inflammatory response to nanoparticle exposure: particle number, surface area, or what?
    Environ Health Perspect 2007, 115:187-194. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  107. Duffin R, Tran L, Brown D, Stone V, Donaldson K: Proinflammogenic effects of low-toxicity and metal nanoparticles in vivo and in vitro: highlighting the role of particle surface area and surface reactivity.
    Inhal Toxicol 2007, 19:849-856. PubMed Abstract | Publisher Full Text OpenURL
  108. Castranova V: Overview of current toxicological knowledge of engineered nanoparticles.
    J Occup Environ Med 2011, 53:S14-S17. PubMed Abstract | Publisher Full Text OpenURL
  109. Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AI, Tyurina YY, Gorelik O, Arepalli S, Schwegler-Berry D, Hubbs AF, Antonini J, Evans DE, Ku BK, Ramsey D, Maynard A, Kagan VE, Castranova V, Baron P: Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice.
    Am J Physiol Lung Cell Mol Physiol 2005, 289:L698-L708. PubMed Abstract |Publisher Full Text OpenURL
  110. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WA, Seaton A, Stone V, Brown S, Macnee W, Donaldson K: Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study.
    Nat Nanotechnol 2008, 3:423-428. PubMed Abstract | Publisher Full Text OpenURL
  111. Porter DW, Hubbs AF, Chen BT, McKinney W, Mercer RR, Wolfarth MG, Battelli L, Wu N, Sriram K, Leonard S, Andrew M, Willard P, Tsuruoka S, Endo M, Tsukada T, Munekane F, Frazer DG, Castranova V: Acute pulmonary dose-responses to inhaled multi-walled carbon nanotubes.
    Nanotoxicology 2013, 7:1179-1194. PubMed Abstract | Publisher Full Text OpenURL
  112. Ma-Hock L, Treumann S, Strauss V, Brill S, Luizi F, Mertler M, Wiench K, Gamer AO, van Ravenzwaay B, Landsiedel R: Inhalation toxicity of multiwall carbon nanotubes in rats exposed for 3 months.
    Toxicol Sci 2009, 112:468-481. PubMed Abstract | Publisher Full Text OpenURL
  113. Mercer RR, Hubbs AF, Scabilloni JF, Wang L, Battelli LA, Schwegler-Berry D, Castranova V, Porter DW: Distribution and persistence of pleural penetrations by multi-walled carbon nanotubes.
  114. Porter DW, Hubbs AF, Mercer RR, Wu N, Wolfarth MG, Sriram K, Leonard S, Battelli L, Schwegler-Berry D, Friend S, Andrew M, Chen BT, Tsuruoka S, Endo M, Castranova V:Mouse pulmonary dose- and time course-responses induced by exposure to multi-walled carbon nanotubes.
    Toxicology 2010, 269:136-147. PubMed Abstract | Publisher Full Text OpenURL
  115. Coin PG, Roggli VL, Brody AR: Persistence of long, thin chrysotile asbestos fibers in the lungs of rats.
    Environ Health Perspect 1994, 102(Suppl 5):197-199. PubMed Abstract | Publisher Full TextPubMed Central Full Text OpenURL
  116. Murphy FA, Poland CA, Duffin R, Al-Jamal KT, Ali-Boucetta H, Nunes A, Byrne F, Prina-Mello A, Volkov Y, Li S, Mather SJ, Bianco A, Prato M, Macnee W, Wallace WA, Kostarelos K, Donaldson K: Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura.
    Am J Pathol 2011, 178:2587-2600. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  117. Schinwald A, Murphy FA, Prina-Mello A, Poland CA, Byrne F, Movia D, Glass JR, Dickerson JC, Schultz DA, Jeffree CE, Macnee W, Donaldson K: The threshold length for fiber-induced acute pleural inflammation: shedding light on the early events in asbestos-induced mesothelioma.
    Toxicol Sci 2012, 128:461-470. PubMed Abstract | Publisher Full Text OpenURL
  118. Stoehr LC, Gonzalez E, Stampfl A, Casals E, Duschl A, Puntes V, Oostingh GJ: Shape matters: effects of silver nanospheres and wires on human alveolar epithelial cells.
  119. Dick CA, Singh P, Daniels M, Evansky P, Becker S, Gilmour MI: Murine pulmonary inflammatory responses following instillation of size-fractionated ambient particulate matter.
    J Toxicol Environ Health A 2003, 66:2193-2207. PubMed Abstract | Publisher Full Text OpenURL
  120. Zhang Q, Kusaka Y, Sato K, Nakakuki K, Kohyama N, Donaldson K: Differences in the extent of inflammation caused by intratracheal exposure to three ultrafine metals: role of free radicals.
    J Toxicol Environ Health A 1998, 53:423-438. PubMed Abstract | Publisher Full Text OpenURL
  121. Hsiao IL, Huang YJ: Effects of various physicochemical characteristics on the toxicities of ZnO and TiO nanoparticles toward human lung epithelial cells.
    Sci Total Environ 2011, 409:1219-1228. PubMed Abstract | Publisher Full Text OpenURL
  122. Warheit DB, Hoke RA, Finlay C, Donner EM, Reed KL, Sayes CM: Development of a base set of toxicity tests using ultrafine TiO2 particles as a component of nanoparticle risk management.
    Toxicol Lett 2007, 171:99-110. PubMed Abstract | Publisher Full Text OpenURL
  123. Sayes CM, Wahi R, Kurian PA, Liu Y, West JL, Ausman KD, Warheit DB, Colvin VL:Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells.
    Toxicol Sci 2006, 92:174-185. PubMed Abstract | Publisher Full Text OpenURL
  124. Simon-Deckers A, Gouget B, Mayne-L’hermite M, Herlin-Boime N, Reynaud C, Carriere M:In vitro investigation of oxide nanoparticle and carbon nanotube toxicity and intracellular accumulation in A549 human pneumocytes.
    Toxicology 2008, 253:137-146. PubMed Abstract | Publisher Full Text OpenURL
  125. Grassian VH, O’Shaughnessy PT, Adamcakova-Dodd A, Pettibone JM, Thorne PS:Inhalation exposure study of titanium dioxide nanoparticles with a primary particle size of 2 to 5 nm.
    Environ Health Perspect 2007, 115:397-402. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  126. Wallace WE, Keane MJ, Mike PS, Hill CA, Vallyathan V, Regad ED: Contrasting respirable quartz and kaolin retention of lecithin surfactant and expression of membranolytic activity following phospholipase A2 digestion.
    J Toxicol Environ Health 1992, 37:391-409. PubMed Abstract | Publisher Full Text OpenURL
  127. Zhang LW, Baumer W, Monteiro-Riviere NA: Cellular uptake mechanisms and toxicity of quantum dots in dendritic cells.
    Nanomedicine (Lond) 2011, 6:777-791. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  128. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E:Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.
    Nat Immunol 2008, 9:847-856. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  129. Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I, Tschopp J: Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta.
    Proc Natl Acad Sci U S A 2010, 107:19449-19454. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  130. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, Klaessig F, Castranova V, Thompson M: Understanding biophysicochemical interactions at the nano-bio interface.
    Nat Mater 2009, 8:543-557. PubMed Abstract | Publisher Full Text OpenURL
  131. Asati A, Santra S, Kaittanis C, Perez JM: Surface-charge-dependent cell localization and cytotoxicity of cerium oxide nanoparticles.
  132. Nagy A, Steinbruck A, Gao J, Doggett N, Hollingsworth JA, Iyer R: Comprehensive analysis of the effects of CdSe quantum dot size, surface charge, and functionalization on primary human lung cells.
    ACS Nano 2012, 6:4748-4762. PubMed Abstract | Publisher Full Text OpenURL
  133. Stebounova LV, Guio E, Grassian VH: Silver nanoparticles in simulated biological media: a study of aggregation, sedimentation, and dissolution.
    J Nanopar Res 2011, 13:12. OpenURL
  134. Ma R, Levard C, Marinakos SM, Cheng Y, Liu J, Michel FM, Brown GE, Lowry GV: Size-controlled dissolution of organic-coated silver nanoparticles.
    Environ Sci Technol 2012, 46:752-759. PubMed Abstract | Publisher Full Text OpenURL
  135. Naim B, Zbaida D, Dagan S, Kapon R, Reich Z: Cargo surface hydrophobicity is sufficient to overcome the nuclear pore complex selectivity barrier.
  136. Chandler D: Interfaces and the driving force of hydrophobic assembly.
    Nature 2005, 437:640-647. PubMed Abstract | Publisher Full Text OpenURL
  137. Donaldson K, Stone V, Clouter A, Renwick L, MacNee W: Ultrafine particles.
    Occup Environ Med 2001, 58:211-216.
    PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL
  138. Knaapen AM, Borm PJ, Albrecht C, Schins RP: Inhaled particles and lung cancer.
    Part A: Mechanisms. Int J Cancer 2004, 109:799-809. OpenURL
  139. Monteiller C, Tran L, MacNee W, Faux S, Jones A, Miller B, Donaldson K: The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area.
    Occup Environ Med 2007, 64:609-615. PubMed Abstract | Publisher Full Text |PubMed Central Full Text OpenURL
  140. Park MV, Neigh AM, Vermeulen JP, de la Fonteyne LJ, Verharen HW, Briede JJ, van Loveren H, de Jong WH: The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles.
    Biomaterials 2011, 32:9810-9817. PubMed Abstract | Publisher Full Text OpenURL
  141. Hussain S, Boland S, Baeza-Squiban A, Hamel R, Thomassen LC, Martens JA, Billon-Galland MA, Fleury-Feith J, Moisan F, Pairon JC, Marano F: Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount.
    Toxicology 2009, 260:142-149. PubMed Abstract | Publisher Full Text OpenURL
  142. Harington JS, Macnab GM, Miller K, King PC: Enhancement of haemolytic activity of asbestos by heat-labile factors in fresh serum.
    Med Lav 1971, 62:171-176. PubMed Abstract OpenURL
  143. Nolan RP, Langer AM, Harington JS, Oster G, Selikoff IJ: Quartz hemolysis as related to its surface functionalities.
    Environ Res 1981, 26:503-520. PubMed Abstract | Publisher Full Text OpenURL
  144. Rajh T, Nedeljkovic M, Chen LX, Poluektov O, Thurnauer MC: Improving optical and charge separation properties of nanocrystalline TiO2 by surface modification with vitamin C.
    J Phys Chem 1999, 103:3515. Publisher Full Text OpenURL
  145. Rothen-Rutishauser BM, Kiama SG, Gehr P: A three-dimensional cellular model of the human respiratory tract to study the interaction with particles.
    Am J Respir Cell Mol Biol 2005, 32:281-289. PubMed Abstract | Publisher Full Text OpenURL
  146. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE: Reconstituting organ-level lung functions on a chip.
    Science 2010, 328:1662-1668. PubMed Abstract | Publisher Full Text OpenURL
  147. Hermanns MI, Unger RE, Kehe K, Peters K, Kirkpatrick CJ: Lung epithelial cell lines in coculture with human pulmonary microvascular endothelial cells: development of an alveolo-capillary barrier in vitro.
    Lab Invest 2004, 84:736-752. PubMed Abstract | Publisher Full Text OpenURL
  148. Klein SG, Hennen J, Serchi T, Blomeke B, Gutleb AC: Potential of coculture in vitro models to study inflammatory and sensitizing effects of particles on the lung.
    Toxicol In Vitro 2011, 25:1516-1534. PubMed Abstract | Publisher Full Text OpenURL
  149. Klein SG, Serchi T, Hoffmann L, Blömeke B, Gutleb AC: An improved 3D tetraculture system mimicking the cellular organisation at the alveolar barrier to study the potential toxic effects of particles on the lung.
    Particle and Fibre Toxicology 2013, 10:31. PubMed Abstract | BioMed Central Full Text |PubMed Central Full Text OpenURL
Fonte: PFT